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Tuberculosis:
a re‐emerging disease in animals and humans
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Summary
Tuberculosis continues to be an important
disease both in humans and animals. It causes
morbidity, mortality and economic loss
worldwide. The occurrence of Mycobacterium
bovis disease in humans, domesticated and
wild animals confirms the relevance of this
zoonosis. M. bovis in humans continues to be
reported in industrialised countries and in
immigrants from regions of the world where
tuberculosis in cattle is endemic. The real
incidence of M. bovis in humans in developing
countries continues to be roughly under‐
estimated due to the scarcity of appropriate
laboratory facilities to isolate and to differ‐
entiate M. bovis strains. In Latin America, less
than 1% of tuberculosis cases are reported as
being due to M. bovis. However, the economic
relevance that meat and dairy industries play
in these countries stimulates the promotion of
bovine tuberculosis eradication programmes.
Human‐to‐human airborne transmission of
M. bovis does occur and it may be important
where human immunodeficiency virus (HIV)
infection in humans is prevalent, M. bovis
infection in cattle is enzootic and pasteuris‐
ation of dairy products is not routinely
practised. Eradication of M. bovis in cattle and
pasteurisation of dairy products are the
cornerstones of prevention of human disease.

Measures should be developed to identify and
control M. bovis infection in wild animals as
these may be important reservoirs of infection
for domesticated food‐producing animals.
There is a need for medical and veterinary
professionals to cooperate on disease outbreaks.
The information presented herein strongly
supports the ‘One World/One Health/One
Medicine’ concept.
Keywords
Health, Mycobacterium, Mycobacterium bovis,
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Tubercolosi: una malattia
riemergente nell’uomo e negli
animali
Riassunto
La tubercolosi (TB) continua ad essere una malattia
importante per uomo e animali. È causa di
morbilità, mortalità e di perdite economiche a livello
internazionale. L’insorgenza della malattia da
Mycobacterium bovis nell’uomo e negli animali
domestici e selvatici conferma la rilevanza di questa
zoonosi. Il M. bovis nell’uomo continua a
manifestarsi
nella
popolazione
dei
paesi
industrializzati e negli immigrati provenienti da
regioni del mondo dove la TB del bestiame ha
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assunto carattere endemico. La reale incidenza del
M. bovis nella popolazione dei paesi in via di
sviluppo continua a essere colpevolmente sotto‐
stimata a causa della mancanza di laboratori adatti
a isolare il micobatterio e sa differenziarne i ceppi.
In America latina, i casi di TB dovuti al M. bovis
sono inferiori all’1%, tuttavia, il peso economico
che le industrie di carni e latticini hanno in questi
paesi incentiva l’introduzione di programmi di
eradicazione. La trasmissione aerea del M. bovis da
uomo a uomo può avere rilevanza laddove si osserva
una prevalenza dell’infezione da virus dell’immuno‐
deficienza umana (HIV). L’infezione da M. bovis
nel bestiame è enzootica e la pastorizzazione dei
latticini non è una prassi di routine. L’eradicazione
di M. bovis nel bestiame e la pastorizzazione dei
latticini sono gli elementi cardine della prevenzione
della malattia nell’uomo. Occorre mettere a punto
programmi di intervento per l’individuazione e il
controllo dell’infezione da M. bovis negli animali
selvatici, in quanto possono essere importanti
riserve di infezione per gli animali domestici
domestici allevati a scopi alimentare. I professionisti
medici e veterinari devono unire le forze per
prevenire le epidemie. Le informazioni riportate
depongono fortemente a favore del concetto “Un
solo mondo/Una sola salute/Una sola medicina”.
Parole chiave
Mycobacterium,
Mycobacterium
bovis,
Mycobacterium tuberculosis, Salute pubblica,
Tubercolosi, Una sola salute.

Introduction
Tuberculosis is an important disease in
humans and animals worldwide. The tubercle
bacillus infects over 2 billion people or one
third of the world’s population and it is
estimated that 1.5 to 2 million people die from
tuberculosis each year (254). A total of 95% of
cases occur in people in developing countries.
Worldwide, tuberculosis is one of the leading
causes of deaths caused by infectious disease.
Significant progress has been made towards
the elimination of tuberculosis caused by
Mycobacterium tuberculosis complex from
humans in industrialised countries (71).
However, in many countries where financial
resources are insufficient to support
tuberculosis programmes, only limited
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progress has been made towards the control of
the disease. The development of multi‐drug‐
resistant and extensively drug‐resistant (MDR
and XDR) strains has complicated the
development of efficacious regimens for the
treatment of tuberculosis in humans and has
significantly increased the cost associated with
the use of multiple drug therapies (284).
Moreover, the susceptibility of human
immunodeficiency
virus
(HIV)‐infected
individuals to M. tuberculosis complex is of
major concern to public health officials in
developing countries where acquired immune
deficiency syndrome (AIDS) is rampant (254).
M. bovis accounts for only a small percentage
of the cases of tuberculosis reported in
humans; however, it is a pathogen of significant
economic importance in wild and domestic
animals around the globe, especially in
countries where little information is available
on the incidence of M. bovis infection in
humans (44, 52, 57, 71, 196, 211, 249, 261, 282,
285).
The genus Mycobacterium includes several
species that cause disease in humans and other
animals. The M. tuberculosis complex (Fig. 1)
includes the following:
 M. tuberculosis
 M. canettii
 M. africanum
 M. bovis
 M. pinnipedii
 M. caprae
 M. microti.
The analysis of the M. bovis genome challenged
the
epidemiological
hypothesis
that
M. tuberculosis is a human‐adapted variety of
M. bovis that was acquired from cattle. The
irreversible loss of DNA material uncovered
by the M. bovis genome sequencing project and
the systematic analysis of polymorphisms in a
large number of strains suggest quite a
different scenario (18, 41). This analysis
indicates that M. canettii is probably the
ancestral species of the M. tuberculosis
complex. Successive DNA deletions, starting
by the loss of region RD 9 (RD = regions of
difference),
originated
in
M. africanum,
M. microti and M. bovis. Moreover, M. bovis
bacillus Calmette‐Guérin (BCG) experienced
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further deletions during in vitro adaptation
and the loss of region RD 1 has been
implicated as the region associated with
virulence attenuation. In this view, modern
M. tuberculosis strains originated later from
ancestral M. canettii by loss of M. tuberculosis‐
specific deletion 1 locus (TbD 1).
Tubercle bacilli were identified more than
120 years ago (130). However, definitive
information on the pathogenesis of the
M. canettii
(modern)

M. tuberculosis complex is not available (41).
The tubercle bacillus enters the macrophage by
binding to cell surface molecules of the
phagocyte. Ingestion of the tubercle bacillus by
the phagocytes into the phagosome or
intracytoplasmic
vacuole
protects
the
organism from the bactericidal components of
serum. Following ingestion of the bacillus,
lysosomes fuse with the phagosome to form

M. tuberculosis
(ancestral-like)
M. tuberculosis
(modern)

RDcan

M. africanum
TbD 1
M. microti

M. pinnipedii
M. caprae

RD 9,
others

RD 7,
RD 8,
RD 10

M. bovis
RD 4 4
RD 1,
others

M. bovis
BCG sub-strains

M. canetti
(ancestral)

RDcan regions of difference canettii
TbD 1 Mycobacterium tuberculosis-specific deletion 1 locus
RD
regions of difference

Figure 1
Proposed evolution of Mycobacterium tuberculosis complex from a common ancestral M. canettii strain
During evolution, the ancestral progenitor underwent various deletions (e.g. loss of RDcan, RD 9, RD 4, RD 1 giving
origin to the micro-organisms of the M. tuberculosis complex
The scheme is based on Brosch et al. (18)
Note the two lineages for M. africanum with the more ancestral-like lineage originating prior to the loss of RD 7, RD 8
and RD 10
This scheme is compatible with bovine tuberculosis arising from human tuberculosis
Reproduced from Thoen & Barletta (247) with kind permission from Blackwell Publishing
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phagolysosomes and it is there that the
phagocytes attempt to destroy the bacillus
(244). However, virulent bacilli have the ability
to escape destruction. Virulent mycobacteria
survive inside a mononuclear phagocyte by
inhibiting phagosome fusion with pre‐formed
lysosomes, thereby limiting acidification. It has
been suggested that pathogenicity of
M. tuberculosis complex is a multifactorial
phenomenon requiring the participation of the
cumulative effect of several lipid complexes,
such as lipoarabinomannan and phosphatidyl
inositol mannoside present in the cell walls of
the bacilli (183, 247). Protective immunity
against mycobacterial infections is dependent
on the activation of a cell‐mediated immune
response. Inflammatory cytokines, i.e. inter‐
leukin 1 (IL‐1), IL‐2 and tumor necrosis factor‐
alpha (TNF‐α), produced by mononuclear cells
sensitised by mycobacterial antigens recruit
natural killer T cells, CD4 T cells, CD8 T cells
and gamma delta T cells (213). These cells each
produce cytokines that recruit additional cells
to the site of infection resulting in the
formation of granulomas and containment of
infection (183). Granuloma formation is an
attempt of the host to localise the disease
process. However, in the cases in which the
host response in unable to destroy the bacillus
due to conditions that compromise immune
function resulting in low CD4+T cell counts,
such as old age, stress or HIV reactivation may
occur, resulting in the release of bacilli and
transmission of infection. For details on the
current state of knowledge on granuloma
formation, readers are referred to D.G. Russell
(213).
The susceptibility of different host species
varies for M. tuberculosis complex depending
on the route of exposure, dose of organisms
and virulence of the strain (86, 244). Humans,
non‐human primates and guinea‐pigs are very
susceptible to M. tuberculosis (235). Cattle,
rabbits, and cats are susceptible to M. bovis and
are quite resistant to M. tuberculosis. Wild
hoofed stock are generally susceptible to
M. bovis but few reports are available on the
isolation of M. tuberculosis (85, 142, 218, 234).
Swine and dogs are susceptible to both
M. bovis and to M. tuberculosis (235, 236, 241).
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For the purpose of presentation and
understanding, the information will be divided
into three parts. The first part deals with
tuberculosis in wild animals, the second
provides information on tuberculosis in
domesticated animals and the third part
presents information on tuberculosis in
humans.

Tuberculosis in wild animals
There has been an increased interest in
tuberculosis in wild and captive wild animals
following outbreaks of the disease in animals
in zoos, primate centres, animal colonies and
game parks (85, 142, 227, 234, 239, 256, 283).
The importance of these occurrences of
tuberculosis is emphasised by the difficulty of
replacing some rare and endangered species,
by the economic losses and by the public
health hazard (8, 16, 51, 77, 182, 193, 194, 210,
261, 266, 270, 286).
In the United States and in several other
countries, M. bovis infection in wild animals
has interfered with the eradication of
tuberculosis in cattle (37, 38, 45, 62, 96, 98, 123,
131, 133, 157, 188, 195, 198, 204). In several
areas where bovine tuberculosis has been
eradicated, it was observed that M. bovis
infection in cervids was responsible for
infection in cattle (122, 123). In Michigan,
M. bovis outbreaks were traced to several cattle
herds in 2006 and 2007 resulting in herd
depopulation. This resulted in the loss of
valuable blood lines and the loss of income
related to the export of breeding animals and
semen. Estimates indicate that the overall
cost of the M. bovis outbreaks in deer and
cattle in Michigan exceeded US$100 million
(M.J. Gilsdorf,
personal
communication).
Efforts to control and eradicate tuberculosis in
wild animals is hampered by a lack of
validated in vivo and in vitro diagnostic tests of
suitable sensitivity and specificity and
procedures for handling and restraining
animals under field conditions to conduct
tuberculin skin tests and/or collect specimens
for laboratory examination to confirm a
diagnosis (241, 248). Therefore, measures need
to be developed to identify and eradicate
M. bovis infection in wild animals.
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Moreover, elimination of tuberculosis from
wild animals has been hampered by the lack of
suitable regulations to limit the sale and
transportation of infected or exposed animals.
The problem is further magnified by the
inability to detect tuberculous animals early in
the course of disease because clinical signs are
often not present until progressive pulmonary
disease develops. Available diagnostic tests
(i.e. tuberculin skin tests, gamma interferon
assays or the enzyme‐linked immunosorbent
assay [ELISA]) should be interpreted with
caution because the criteria for conducting
these tests have not been systematically
evaluated in many species. However, positive
tuberculin reactions usually indicate infection
or previous exposure to mycobacteria. It
should be emphasised that negative results are
of questionable significance in instances
especially when animals have been exposed to
M. bovis. The time period for development of
delayed hypersensitivity varies for different
species and for individual animals in a
population in which tuberculosis has been
diagnosed.

Distribution
Some early reports of tuberculosis describe the
disease seen in wild animals in zoos or animal
parks (85, 218, 239, 271). In view of the
reduction of tuberculosis in domestic animals
and humans, one might expect a decrease in
the disease in zoo animals. However, there is
evidence to indicate that foci of infection may
persist in some wild animal populations for
long periods of time (42, 85, 90, 133, 135, 204,
233, 256, 272). Moreover, no regulations exist
in many countries which require tuberculosis
outbreaks in wild or captive wild animals to be
reported to regulatory or public health
officials. In many instances, necropsies are not
conducted. In addition, there is often a
reluctance to publicise the occurrence of
tuberculosis in these animals because of public
relations and loss of revenue (286).
Tuberculosis has not been commonly reported
in wild animals, except where they have been
exposed to domestic animals or to humans that
have the disease (136, 155, 156, 159). The
majority of these are considered spill‐over
cases, where infection is present but not
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sustainable in the wildlife population (45, 64,
123, 157). M. bovis‐infected cattle are considered
the most probable reservoir hosts (123). When
tuberculosis in cattle in the same geographic
areas was eliminated or reduced, comparable
declines in the prevalence in wildlife were also
seen (39, 101, 149, 186). However, there are
now several species of wildlife that are
recognised as reservoirs of M. bovis. The major
wildlife reservoirs for M. bovis are ungulates,
including African buffalo (Syncerus caffer) (12,
65, 126, 133, 157) wood bison (Bison bison
athabascae) (131, 177) and North American
bison (Bison bison) (73, 96, 131, 229).
Several species of cervids susceptible to
M. bovis (16, 37, 64, 68, 72, 80, 101, 118, 179, 202,
203, 204, 217, 220, 256, 263, 265), such as white‐
tailed deer (Odocoileus virginianus) (11, 88, 121,
135, 180, 188, 219), mule deer (Odocoileus
hemionus) (210) and lechwe (Kobus lechwe) (33,
91, 275) are recognised as reservoirs. Red
deer/elk/wapiti (Cervus elaphus) subspecies
(131, 177, 197, 198, 228, 233, 243, 262, 263) are
also reservoirs for M. bovis in some instances.
European badgers (Meles meles) are a reservoir
species in the United Kingdom (10, 36, 38, 39,
136, 152, 174). Brushtail possums (Trichosurus
vulpecula) are a recognised reservoir of M. bovis
in New Zealand (42, 43, 63). Feral swine (Suis
scrofa) and wild boar (Sus scrofa) were once
considered to be spill‐over hosts for M. bovis
(6, 45, 69, 73, 149, 197, 223); however,
mounting evidence in Europe indicates that
wild boars have become reservoirs of M. bovis
for other wildlife and domestic animal species
(99, 176, 191, 262, 263).
Other wildlife species have been reported with
M. bovis infection that have a potential to be
reservoirs of M. bovis; but have not been
implicated as reservoirs of the disease. Wild
cloven‐hoofed animals with M. bovis infection
include free‐ranging axis deer (Axis axis) in
Hawaii (72, 217), greater kudu (Tragelaphus
strepsiceros) (128, 157), llama (Lama glama) (9,
258), fallow deer (Dama dama) (6, 16, 58, 281),
roe deer (Capreolus capreolus) (58, 105), muntjac
(Muntiacus spp.) (58), giraffe (Giraffa
camelopardalis) (84, 197, 218), ferret (Mustela
furo) (45, 64), feral water buffalo (Bubalis
bubalis) (45, 108), Arabian oryx (Oryx leucoryx)
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(81), Sika deer (Cervus nippon) (58, 68, 167),
tapir (Tapirus terrestris) (195), mule deer (210),
European wild goat (Capra aegagrus) (195),
impala (Aepyceros melampus) (157), sitatunga
(Tragelaphus spekii) (195), Bactrian camel
(Camelus ferus) (21, 195), large spotted genet
(Genetta tigrina) (157), wildebeest (Connochaetes
spp.), lesser kudu (Tragelaphus imberbis) and
topi (Damaliscus korrigum) (34), yak (Bos
grunniens) (218) and eland (Taurotragus oryx)
(157, 195).
Carnivores and scavengers can acquire
M. bovis under natural conditions through the
consumption of infected carcasses. These
species include the fennec fox (Fennecus zerda)
(111), tiger (Panthera tigris) (145, 218), coyote
(Canis latrans) (19, 180, 181), wolf (Canis lupus)
(22), fox (Vulpes vulpes) (19, 58, 136), lion
(Panthera leo) (126, 157, 171, 218), cheetah
(Acinonyx jubatus) (126, 157), leopard (Panthera
pardus) (157, 218), snow leopard (Uncia uncia)
(109), weasel (Mustela spp.) (45), Iberian lynx
(Lynx pardinus) (6, 17), bobcat (Felis rufus) (19,
180), hyena (Crocuta spp.) (155, 157), raccoon
(Procyon lotor), black bear (Ursus americanus)
and opossums (Didelphis virginiana) (19, 136,
198), mustelids (Mustela spp.) (8, 61, 144, 206,
207), stoats (Mustela erminea) (58, 205), bush pig
(Potamochoerus porcus) (157) and warthogs
(Phacochoerus africanus) (157).
Other wildlife species affected by M. bovis
include moles (Scalopus aquaticus) (58), voles
(Clethrionomys spp., Microtus spp.) (58, 90, 152),
rats (Rattus spp.) (58), hedgehogs (Erinaceous
europaeus) (58, 143), rabbits (Oryctolagus
cuniculus cuniculus) (45, 95, 127), European
badgers
(58,
157),
white
rhinoceros
(Ceratotherium simum) (51, 227), hares (Lepus
europaeus) (6), primates including a Siamang
gibbon (Symphalangus syndactylus), Mayotte
lemur (Lemur fulvus mayottensis), lion tailed
macaque (Macaca silenus) and Patas monkey
(Erythrocebus patas) (271), Colobus monkeys
(Colobus guereza caudatus) (227), baboons (Papio
spp.) (127, 216, 232, 238, 253), otters (Lutra
lutra) (58) and Arctic marine mammals (257).
Tuberculosis caused by M. pennipidii, a variant
of M. bovis has been reported in fur seals
(Arctocephalus spp. and Arctocephalus forsteri)
and sea lions (Neophoca cinerea) (48, 276). The
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organism has been reported to cause disease in
cattle, gorillas, tapirs and llamas (47). Also,
M. pennipidii has been isolated from a trainer of
seals in New Zealand (251). Mycobacterium
caprae has been isolated from a dromedary
camel (Camelus dromedarius) and North
American bison (193). The lesions observed
closely
resembled
M. bovis
infection.
M. africanum has been isolated from a monkey
(252) and M. microti has been isolated from
wild voles (Microtus agrestis) and wood mice
(Apodemus sylvaticus) (58, 267).
M. bovis has been isolated from captive and
wild non‐human primates in several countries
(34, 127, 157, 216, 227, 232, 234, 238, 271, 273,
283). Tuberculous humans have been the
source of M. tuberculosis infection in Asian
elephants (Elephas maximus) (154, 159). In
addition,
M. tuberculosis
has
caused
tuberculosis in non‐human primates (89, 104,
234, 239). M. tuberculosis has been isolated from
captive wild animals (black rhinoceros [Diceros
bicornis], oryx, addax [Addax nasomaculatus]
and Asian elephant and Rocky Mountain goats
[Oreamnos americanus]) originating in nine
states in widespread areas of the United States
(182, 239). Several other species of the genus
Mycobacterium have been isolated from wild
animals maintained in captivity (195, 234, 237,
241). The widespread occurrence of outbreaks
of mycobacterial infections is of concern to
public health officials and to veterinarians
responsible for the health care of wild animals
in zoos, animal parks and primate colonies.

Aetiology
Most clinically significant mycobacteria are
slow growing organisms that usually appear
on culture media in 3 to 6 weeks (241).
Microscopically, the mycobacteria usually
appear as slender rods that are 0.3 to 0.6 μm in
diameter and 1.5 to 3 μm in length (130). The
morphology and staining characteristics of
pathogenic mycobacteria are similar to those of
saprophytic mycobacteria. An important
staining characteristic of mycobacteria is their
resistance to acid decolourising agents. Several
staining procedures are available for
demonstrating acid‐fast bacilli (AFB), but the
Ziehl‐Neelsen or Kinyoun techniques with
carbol fuchsin are most widely used.
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Tubercle bacilli grow aerobically on in vitro
cultivation. The optimal temperature for
growth of mammalian strains is 37°C. To
minimise growth of rapidly growing bacteria
or fungi on culture media, sodium hydroxide
is usually used to process ground tissue
suspensions for inoculation of solid culture
media (69, 241). Pyruvate, when added to
culture medium, enhances the growth of
M. bovis, whereas glycerol inhibits the growth
of M. bovis (110, 125, 249). Liquid culture
techniques (i.e. BACTEC) provide for more
rapid detection (112). Identification of
mycobacterial isolates is accomplished by use
of appropriate biochemical, drug susceptibility
and supplemental tests or by molecular
techniques (106, 260). Polymerase chain
reaction (PCR) conducted on formalin‐fixed
tissues
and/or
cultures
enable
rapid
identification of the M. tuberculosis complex
(162).
Restriction
fragment
length
polymorphism (RFLP) and spoligotyping are
useful
in
strain
differentiation
of
M. tuberculosis and of M. bovis (46, 106). More
recently, multilocus variable number tandem
repeat analysis (MLVA) has been described;
this technique, when used alone or in
combination with other genomic analyses, may
lead to a greater differentiation of M. bovis
strains (3, 151, 224, 231). Genotyping
techniques have been useful in conducting
epidemiological investigations to obtain
information on the source(s) of infection (62,
99, 106, 120, 123, 138, 161, 191, 192, 260).

Transmission and resistance
In non‐human primates, M. tuberculosis
complex can produce extensive disease
involving the parenchyma of the lungs as well
as extrapulmonary tissues (127, 232, 237).
When animals with advanced disease cough,
the organism may be transmitted by aerosol or
droplets of exudate containing the bacilli.
Animals may also be infected by ingestion of
feed and water contaminated with urine, faecal
material or exudates from diseased animals
that contain tubercle bacilli. Fomites, such as
thermometers, are a definite source of spread,
as are cages, masks and containers used for
food and water.
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In addition, elephant, rhinoceros and oryx are
examples of animals that appear to be
susceptible to M. tuberculosis (142, 159). Oryx
may develop extensive pulmonary lesions as
well as lesions of the uterus and mammary
gland. Therefore, in the young, congenital
transmission, or transmission by drinking milk
from an animal with tuberculous mastitis, may
be a factor. Tuberculous humans may also be a
source of infection for both susceptible hoofed
animals and non‐human primates (154, 156,
159). Therefore, measures should be taken to
protect these animals from humans infected
with M. tuberculosis.
Crowding appears to be important in the
transmission and spread of tuberculosis in
wild animals as in humans. The disease is most
common among animals kept in close contact
in exhibit pens or barns, or where
supplemental feeding is practised (122, 163,
165).

Signs
It is important to emphasise that clinical signs
are only rarely apparent in wild animals.
Clinical signs of tuberculosis, when present in
wild mammals, are often variable. The
extensiveness of disease is related to the
virulence of the organisms, the route of
infection, the stage of infection and several
host‐related factors. Wild animals with
pulmonary tuberculosis may exhibit a cough
and show some evidence of dyspnoea. When
visceral lesions are present, an enlarged spleen
and/or liver may be palpated on physical
examination. Regional lymph nodes may be
enlarged in advanced cases and, in some
instances, may rupture and drain to the
surface. Emaciation may result from
inappetence in chronic cases. The hair coat
may appear rough and occasionally alopecia is
apparent. In acute cases resulting from
massive exposure to M. tuberculosis complex,
the disease may spread rapidly and no obvious
signs develop prior to death.
Tubercles are often found in bronchial,
mediastinal and portal lymph nodes. Other
tissues that may be affected include lungs,
liver, spleen and the surfaces of body cavities.
When tuberculous lesions are located in the
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parenchyma of lungs, a productive broncho‐
pneumonia may be present. Dyspnoea,
emaciation and a roughened hair coat are
apparent in animals with advanced disease. In
some cases where generalised tuberculosis is
present, lesions have been reported in the
genital tract. A mucopurulent discharge from
the vagina may persist for prolonged periods
of time. The occurrence of tuberculous mastitis
in an oryx emphasised the significance of a
thorough physical examination supported by
adequate laboratory examination (142).
The obvious difficulty with observing and
handling animals in the wild or farmed herds,
or in those in confined colonies, is that animals
with progressive tuberculosis remain in these
populations when no signs of tuberculosis are
present. It is essential to conduct suitable
diagnostic procedures, including delayed type
hypersensitivity tests and in vitro tests while
animals are held in isolation prior to
introduction into a herd or exhibit.

Gross pathology
Wild mammals found to be tuberculous at
necropsy after natural death are often without
prior suspicion of tuberculosis. Gross lesions
may be extensive involving entire organs of
one or both body cavities; however, the
anatomical sites of lesions, the extent of
pathological involvement and the consistency
of nodular formations with some caseous
necrosis are often present before unthriftness is
often apparent (245).
Tuberculous lesions observed at necropsy
usually have an appearance of yellowish
caseous necrotic areas in nodules of firm white
to light grey fibrous tissue. Tubercles may not
appear discrete in instances where lesions
become diffuse with adjacent tissues. Often
other bacteria and agents are present within
tuberculous lesions which may affect gross
appearance. Some lesions observed in lymph
nodes of the head, particularly the medial
retropharyngeal nodes or thoracic cavity of
cervids, may have a purulent consistency,
whereas others may be partially dry (181, 188,
243, 245).
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Microscopic pathology
A tubercle is described as a granulomatous
lesion, characteristically composed of a
caseous, necrotic centre bordered by a zone of
epithelioid cells, some of which may have
formed multinucleated giant cells, an
accumulation of lymphocytes, a few
granulocytes and an encapsulation of fibrous
connective tissue of varying thickness (241).
There is considerable variation in the apparent
ability of some wild mammals to form
tubercles associated with connective tissue and
for epithelioid cells to form multinucleated
giant cells.
Tuberculous lesions from camelids and wild
bovines often contain a central area of
caseation with some mineralisation surrounded
by a zone of epithelioid cells and lymphocytes,
and may be encapsulated by a thick zone of
fibrous connective tissue.
Lesions examined from oryx, kudu, nilgai
(Boselaphus tragocamelus) and sable antelope
(Hippotragus niger) closely resemble those in
other bovidae. Nodular areas of caseation and
epithelioid cells exhibit an apparent lack of
connective tissue involvement.
Tuberculous lesions from baboons and several
species of monkeys usually demonstrate
microscopic similarities with those in other
wild mammals. Tubercles from non‐human
primates infected with M. bovis do not have
significant
histological
differences
to
differentiate them from lesions caused by
M. tuberculosis.

Diagnosis
Clinical signs are of limited value in
establishing a presumptive diagnosis of
tuberculosis in wild animals. Although lesions
may involve several organs in the thoracic and
abdominal cavities, the animal may not show
evidence of disease. Emaciation, dyspnoea and
a roughened hair coat may be apparent in
some advanced cases; however, these may not
be present until a few days or weeks before
death.
Ante‐mortem diagnostic tools used in livestock
have been applied to several wildlife species.
Skin testing has been used widely in captive
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and free‐ranging cloven‐hoofed animals (100,
227, 228, 231, 242, 243, 245); but the sensitivity
and specificity of these tests in wildlife often
vary from those seen in domestic cattle and
raise concerns regarding their use in
tuberculosis control programmes in some
species (265).

free of animal protein. Three strains of
M. tuberculosis were used. The skin test agent
was produced in the same general manner as
KOT, except that it was evaporated to only
20% of its original volume and reconstituted to
40% using phosphate buffered saline
containing 0.5% phenol and glycerol.

In some non‐human primates the tuberculin
skin test remains negative for several weeks
following
exposure.
Despite
certain
limitations, the tuberculin test is considered
the most practical procedure for the diagnosis
of tuberculosis in non‐human primates (89).
Some in vitro cell‐mediated immune assays
have been developed, such as gamma
interferon assay. These assays may be used as
supplemental tests; however, the efficacy of
these tests remains to be determined in many
species. Factors that may influence tuberculin
skin responsiveness in monkeys include
inhibition of the reaction by isoniazid (INH)
therapy, desensitisation following repeated
tuberculin skin testing and infection with
certain viruses, such as rubeola (94, 200).

Refined tuberculins referred to as purified
protein derivatives (PPDs) have been prepared
by the precipitation of culture filtrates on
which M. bovis was grown using ammonium
sulphate or trichloroacetic acid (103). An
advantage of PPDs is that they may be
standardised on the basis of their protein
nitrogen content. Moreover, these products
can be biologically balanced by tests in guinea‐
pigs and/or cattle for use in comparative tests.

Radiological examinations have proved to be
of value in identifying lesions in tuberculous
baboons (238). Advanced cases in non‐human
primates with lung granulomas caused by
M. bovis and M. tuberculosis appear as nodular
masses. Similar findings have been reported in
kudus from which M. bovis was isolated on
necropsy.
Adequate dosage is an important factor in
performing tuberculin tests in non‐human
primates. Tuberculins prepared for human use
are not suitable because the doses are too low.
Products used in non‐human primates must be
standardised in the species to be tested.
Several tuberculins prepared by different
methods are in use for testing exotic animals.
In the past, Koch’s Old Tuberculin (KOT)
originally was prepared from a heated
concentrate of glycerol‐veal broth in which
tubercle bacilli were grown. The bacilli were
killed by flowing steam and removed; the
filtrate was evaporated to 10% of its original
volume. Later, a tuberculin for veterinary use
referred to as ‘old tuberculin’ (OT) was
produced by the United States Department of
Agriculture (USDA) on a synthetic medium
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Tuberculin skin tests in exotic cloven‐hoofed
animals are most often conducted in the
cervical region; in camelids, the tests are
conducted in the axillary region just behind
the front leg. In non‐human primates, one
tenth of a ml (5 000 tuberculin units [TU]) of
USDA‐PPD is usually injected into an upper
eyelid and the site is observed for induration at
24, 48 and 72 h. Tests using biologically
balanced M. avium PPD and M. bovis PPD
tuberculin injected at separate sites on the
abdomen lateral to the linea alba may enable
the differentiation of sensitisation due to
M. tuberculosis complex from that due to
M. avium complex and other acid‐fast
organisms.
In vitro cellular techniques, such as the
lymphocyte proliferation assays (i.e. gamma
interferon assay) using specific mycobacterial
antigens, appear to be of some value. Test
results are available within one week; this
would enable the rapid detection and removal
of infected animals from the population, a very
important aspect in the control and elimination
of the disease. Lymphocyte stimulation tests
have an advantage in that the animals are
handled only once, compared to twice for
tuberculin skin tests; furthermore, the immune
status of the animals is not altered by repeated
skin testing.
Serological tests have been developed to detect
mycobacterial antibodies in wild animals with
disease (23, 34, 240, 241). These tests have not
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permitted definitive diagnoses of tuberculosis
in certain animals, mainly because of non‐
specific reactions and false‐negative reactions
(159). Studies on sera from monkeys infected
with M. bovis indicate the usefulness of ELISA
for the diagnosis of tuberculosis in monkeys
and other wild species with advanced disease
(34, 146, 240). However, tests to detect
antibodies are of little or no value in the
identification of animals in the early stages of
infection (248). The potential use of multiple
antigens in detecting infections in the sera of
wild animals has been reported; however
further investigations are needed to improve
the sensitivity for the tests to be of practical
value in the elimination of disease from
populations in which tuberculosis has been
diagnosed (146, 147, 159).
Histopathological examinations of tissues
collected at necropsy or on biopsy are useful to
establish a diagnosis of tuberculosis. Lesions
may vary for different animals; however,
typical lesions are usually characterised by the
presence of epithelioid cells and multi‐
nucleated giant cells. Caseation necrosis and
mineralisation may be present. Molecular
techniques have been developed for the
detection of M. tuberculosis, M. bovis and
M. avium complex in formalin‐fixed tissue
specimens (162).
Slaughter surveillance is useful in some
animals (i.e. cervids) to identify gross lesions
typical of tuberculosis (265, 281). Tissues
should be collected for culture or PCR
whenever possible because this is the only way
to confirm a diagnosis of tuberculosis.
Specimens for mycobacteriological examin‐
ations should be submitted to a laboratory
either in a saturated solution of sodium borate
or frozen. Since many of the pathogenic strains
of mycobacteria grow slowly, cultures should
be incubated for 8 to 10 weeks at 37°C. PCR
and RFLP are currently available in most
reference diagnostic laboratories (106).

Prevention and control
In instances where the reservoir of tuberculosis
for wildlife is domestic cattle, control and
eradication of the disease in cattle has reduced
spill‐over into susceptible wildlife species (35,
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100, 186). Research on vaccines for potential
use in wildlife is ongoing. Problems exist
regarding the efficacy of vaccines to prevent
disease. Moreover, guidelines have not been
developed for effective vaccine delivery
systems for wildlife (49, 114).
Control of tuberculosis in wildlife populations
is extremely difficult when there is a wildlife
reservoir of disease; efforts have been directed
at reducing levels of disease in the wildlife
species, reducing wildlife population numbers
and keeping infected animals from potential
hosts (64, 177, 181). Cases in point include
M. bovis in badgers in the United Kingdom,
brushtail possums in New Zealand elk, white‐
tailed and mule deer in the United States,
bison in Canada and African buffalo in South
Africa.
Sporadic cases of tuberculosis in free‐ranging
white‐tailed deer and mule deer have been
reported (11, 135, 195) but these cases were
isolated incidents and attributed to spill‐over
from infected cattle herds. It has been
hypothesised that the initial infection of white‐
tailed deer with M. bovis in Michigan occurred
in the 1930s, when severe winters drove deer
onto cattle farms with high levels of
tuberculosis (165, 180). The area currently
affected by bovine tuberculosis has been
concentrated in this region: the north‐eastern
lower peninsula of Michigan (165, 180, 219).
Until the current disease outbreak in 1994,
traditional paradigms assumed that the
normal behaviour of white‐tailed deer, a non‐
herding species, would not provide sufficient
opportunities for disease transmission to
develop endemic tuberculosis (11, 195).
However, the seasonal aggregation of deer in
‘yarding areas’ in the winter for shelter and
feed, the practice of large‐scale supplemental
winter feeding of deer by residents and contact
between infected does and their fawns have
provided sufficient opportunity for disease
transmission (163, 180, 219).
After recognition of the presence of endemic
bovine tuberculosis in Michigan, several
control measures have been implemented to
control and eradicate the disease in wildlife.
Active surveillance of wildlife and livestock,
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and bans on supplemental feeding of deer,
combined with measures to reduce the size of
the deer herds in the tuberculosis‐affected area
were initiated and the prevalence of
tuberculosis in wild deer has declined from a
peak over 2% in the late 1990s to 0.3% in 2007;
(158). Spill‐over from infected deer from 1996
to 2003 has been seen in coyotes, raccoons,
black bears, elk, bobcats, red foxes and
opossums (19, 158, 180).
Wild animals acquired for zoos, animal parks
or primate colonies should come from sources
known to be free of disease. Quarantine should
be imposed on imported animals; the period of
quarantine should be a minimum of 60 days
and preferably 120 days. When tuberculosis is
diagnosed in an animal colony or holding
facility, it is necessary to thoroughly clean and
decontaminate the facilities using a substituted
cresylic such as 1‐Environ at 7 to 19 day
intervals.

Treatment
Anti‐tuberculosis drugs used in humans have
been used to treat disease in elephants,
monkeys, oryx, addax, giraffe and great apes
in captivity. The dosage and period of time for
which animals are maintained on drug(s)
appear to be variable to obtain and maintain
suitable blood levels to inhibit tubercle bacilli
(84, 89, 159, 268, 273). Two or more anti‐
tuberculosis drugs (i.e. INH), rifampin or
ethambutol) should be used simultaneously
when treating animals that have signs of
disease (234, 273). In vitro drug susceptibility
tests should be conducted on cultures prior to
initiation of long‐term therapy; these tests
should be repeated on recent isolates at
periodic intervals if animals fail to respond to
therapy. Assistance should be obtained from a
reference laboratory that can conduct tests to
determine drug susceptibility profiles.
There is evidence that INH is immuno‐
suppressive; therefore, the use of the
tuberculin test to detect tuberculous animals in
a colony receiving INH therapy may be of
limited value (94). To obtain a valid test, it is
recommended
that
INH
therapy
be
discontinued 30 days prior to tuberculin skin
testing of animals. The risk that infected
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animals will develop fulminating disease is a
reason often presented for failure to
discontinue drug therapy prior to conducting
delayed‐type tuberculin skin tests.
INH is an inexpensive drug used to treat
elephant, non‐human primates, giraffe, camels
and some other wild animals (23, 85, 87, 89,
159, 234, 273). The INH dosage in elephant or
monkeys ranges from 7.5 to 20 mg/kg per day
for 3 months to 1 year; however, a lower dose
is recommended in new world monkeys. The
drug may be added to food or fruit juice or
dissolved in water. The water intake may vary
considerably from one day to another under
various environmental conditions; therefore,
the addition of INH to food ensures more
uniform ingestion. In elephant, INH can be
placed in the rectum in animals that refuse to
accept the drug by oral administration.
(G. West, personal communication). For
cloven‐hoofed animals, such as kudu, oryx,
llama and rhinoceros, INH should be
administered at the rate of 5‐10 mg/kg per day
for 1 year, and may be reduced during the
second year of therapy (234). Peracute deaths
have been reported in giraffe treated with INH
(84). Ethambutol and rifampim have been used
in treating Arabian oryx (J. Haagsma, personal
communication). Para‐aminosalicylic acid
(PAS) and streptomycin are other drugs which
have been used to treat animals infected with
M. tuberculosis complex.

Tuberculosis in domestic
animals
Cattle
Distribution of disease
Tuberculosis due to M. bovis is found in cattle
throughout the world. The disease was
probably introduced into the Americas in
colonial times by imported cattle. Tuberculosis
was prevalent in cattle in Europe, with areas
showing as many as 50% of the animals
infected. Where eradication programmes have
been conducted, bovine tuberculosis has
decreased considerably and it has been
eliminated in some Scandinavian and
European countries; however, in some
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developing countries of Africa, Asia and South
America, the occurrence of tuberculosis in
cattle remains extremely high. Outbreaks
continued to occur in 2007 and 2008 in
widespread geographic areas of the United
States (California, Minnesota, New Mexico,
Colorado, Oklahoma and Michigan) (Michael
Carter, personal communication).
Once considered to be a rarity, wildlife
reservoirs of M. bovis infection are being
recognised as serious impediments to the
control of tuberculosis in cattle in areas where
control and eradication programmes were able
to virtually eliminate the disease from
livestock (96, 123). In the United Kingdom,
New Zealand, Canada, South Africa and the
United States, wildlife reservoirs of M. bovis
(European badgers, brushtail possums, elk,
bison, African buffalo and white‐tailed deer,
respectively) have interfered with the
eradication of tuberculosis in cattle (123).
While it has been suggested that cattle were
originally the most likely source of M. bovis for
the wildlife hosts, each of these host species
was capable of sustaining M. bovis once the
disease became established in the free‐ranging
wildlife population (133, 164, 172, 181, 186,
204). Genomic analysis demonstrating that
cattle share M. bovis with wildlife (6, 46, 99,
106, 151) and levels of bovine tuberculosis in
cattle have been linked to the prevalence of the
disease in wildlife (39, 74,101, 149, 181).
The presence of wildlife reservoirs of
tuberculosis creates a serious barrier to the
eradication of the disease in livestock (96, 98,
131, 133, 204). Disease control in wildlife is
difficult, and outbreaks of tuberculosis in cattle
due to exposure to wildlife are very costly. In
the United States, estimates of the overall cost
of M. bovis outbreaks in farmed and wild deer
and cattle in the State of Michigan was in
excess of US$100 million (96). In Canada, the
estimated cost of management strategies of
bovine tuberculosis in the Riding Mountain
area is US$1.5 million annually (131). Current
approaches to control this aspect of
tuberculosis include increasing biosecurity
measures to separate infected wildlife from
cattle, feed, water, and cattle housing,
reducing the size of the wildlife reservoir
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population and reducing/controlling levels of
tuberculosis in wildlife (101, 173, 214).
Measures need to be developed to identify and
eradicate M. bovis infection in wild animals
since these animals are an important source of
infection for domestic food‐producing animals.
M. tuberculosis is only rarely isolated from
cattle. Lesions generally are limited to lymph
nodes of the head. Cattle exposed to
tuberculous caretakers often respond to
tuberculin skin tests. Therefore, the importance
of hypersensitivity due to M. tuberculosis
infection in cattle should be considered only in
herds where no gross lesion responses are
routinely reported.
Tuberculosis in cattle has decreased where
control and eradication programmes have
been based on tuberculin testing and slaughter
of reactor animals. In the United States in 1916,
0.53% of the cattle examined on post‐mortem
were condemned for tuberculosis whereas in
1978 less than 0.0016% were condemned for
this disease. During a five‐year period from
1972 to 1977, M. bovis was isolated from cattle
originating in 32 states and Puerto Rico (241).
In 2007 and 2008, M. bovis was identified in
14 herds in 6 states. (Michael Carter, personal
communication). These occurrences emphasise
the need to maintain efforts to identify foci
early in order to minimise the spread of
disease to other herds through the sale and
movement of M. bovis‐infected cattle.

Aetiology and transmission
M. bovis, a slowly growing non‐chromogenic
acid‐fast bacterium, is the agent most often
responsible for bovine tuberculosis (237).
However, M. caprae has been isolated from
cattle in several countries in central Europe
(195). Among cattle, the tubercle bacillus is
transmitted
through
the
air
or
by
contaminated feed and water. It has been
shown that mycobacteria can be isolated from
the nasal secretions of cattle reacting to
tuberculin. Pulmonary exudates of the cow are
usually
swallowed;
consequently,
the
organisms pass with the faeces to contaminate
the ground and feed. Congenital transmission
of tuberculosis has been recorded. Genital
lesions have been reported; therefore, the
importance of spread by this route should be
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considered in a herd where infection persists.
By comparison, the different serovars of
M. avium complex isolated from lesions in
slaughter animals, with few exceptions, caused
only localised lesions in the mesenteric lymph
nodes and other tissues.

Signs and pathology
The signs of tuberculosis in cattle usually vary
with the distribution of tubercles in the body
(241). Clinical evidence of disease may not
become apparent in chronic cases until the
terminal stages of disease. In cases where
progressive pulmonary disease exists, the
animals may show signs of dyspnoea with an
associated cough. The pathogenesis and
observation of gross lesions in cattle are
similar to those reported previously in this
chapter for wild animals. Microscopic
examination of tubercles in the lungs usually
reveals central areas of necrosis and
mineralisation, with borders of epithelioid
cells and well‐defined capsules composed of
fibrous connective tissue. Multinucleated giant
cells are commonly observed.

Diagnosis
Since clinical evidence of disease is usually
lacking in tuberculous cattle, a presumptive
diagnosis is often made on the basis of an
animal’s response to tuberculin injected into
the skin of the caudal fold (caudal‐fold
tuberculin [CFT] test). The tuberculin skin test
has been referred to as the master key to
bovine tuberculosis control and eradication
programmes in many countries of the world
(175, 266). Much has been written about the
sensitivity of different test sites and the
various tuberculins available for use in cattle
(124, 184, 185, 186). PPD tuberculins have been
produced for veterinary use from the culture
filtrate of M. bovis (103). These products, when
used with biologically balanced M. avium PPD
in a comparative cervical skin test (CCT),
provide
useful
information
for
the
differentiation of skin responses caused by
M. bovis from those caused by other
mycobacteria (248).
Gamma interferon assays have been developed
for use in detection of M. bovis infection in
cattle (264, 274). The specificity of this test has
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been improved by the use of specific
mycobacterial antigens (i.e. ESAT‐6) in cattle
(199). These assays have been evaluated as a
supplemental test in some countries. Studies in
cattle experimentally infected with M. bovis
suggest that skin testing affects gamma
interferon and antibody responses (187).
Information is needed in cattle naturally
infected with M. bovis under field conditions in
different regions of a country.
Serological tests have been developed for
detecting bovine tuberculosis; but these tests
have not been widely used because they fail to
have adequate sensitivity to detect animals in
the early stages of disease and because of
problems
associated
with
non‐specific
reactions (248). The lack of sensitivity of ELISA
and other serological tests is important
because a large percentage of the M. bovis‐
infected cattle in a herd are often not in
advanced stages of disease. However, ELISA
may be of some limited value in slaughter
surveillance to detect cattle with advanced
disease.
To confirm a diagnosis of tuberculosis, it is
necessary to isolate and identify the
aetiological agent using bacteriological
procedures and/or molecular techniques (106,
241, 248).

Vaccination and treatment
Vaccination with BCG has been attempted in
cattle in Africa and other countries with no
success (175, 285). Vaccination with BCG has
not come into widespread use as BCG often
provides only partial protection in cattle (20).
Some evidence indicates BCG plus ESAT‐
6:CFP10 confers some protection in cattle that
have been experimentally exposed to M. bovis;
however, information is not provided on the
time interval at which animals were
necropsied following challenge (153). At the
present time, no practical or effective
approaches have been developed for
vaccinating animals against M. bovis. It is
important to emphasise that some vaccinated
animals develop disease and are contagious;
these animals may remain in the herd and
serve as sources of infection for other animals.
BCG vaccination of cattle has been abandoned
because of the low protective effect and
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because BCG vaccination interferes with the
tuberculin testing used in eradication
programmes (277).

differentiated consistently, on either gross or
microscopic examination from those caused by
M. avium.

More recently, there has been an increased
interest
in
DNA
vaccination
against
tuberculosis (32, 114). With the availability of
the genome sequence of M. bovis, it may now
be possible to evaluate protective DNA
sequences (92). Moreover, DNA vaccines may
not elicit delayed hypersensitivity responses;
therefore, they would have the advantage of
not interfering with the tuberculin skin test or
the gamma interferon assay. It should be
emphasised that evaluation of new vaccines
must be conducted in naturally occurring
outbreaks of M. bovis under field conditions
(186).

Swine are quite susceptible to M. bovis (235).
Progressive lesions are usually observed in the
lungs; well‐defined tubercles may be present
in the liver, spleen and lymph nodes in the
thoracic
and
abdominal
cavities.
Microscopically, granulomas may contain
caseated centres with some mineralisation.
Giant cells and epithelioid cells are usually
present in lesions in the lungs. Although AFB
can be demonstrated on appropriately stained
sections, it should be emphasised that only a
few tubercle bacilli may be observed.
Outbreaks of infection are usually found on
premises where tuberculosis has been
diagnosed in cattle. Yards or buildings
contaminated with faecal material that
contains viable organisms may serve as a
source of infection. Milk from infected cows
has also been cited as a possible source of
tubercle bacilli. Animals are usually infected
by ingestion of the organism. There is little
evidence
for
pig‐to‐pig
transmission.
Tuberculin tests conducted by injection of
5 000 TU of PPD in the skin of the dorsal
surface of the ear or vulva are useful for
diagnosis.

Some anti‐tuberculosis drugs have been
evaluated in treatment of tuberculous cattle.
However, no systematic studies have been
made to ascertain the efficiency of these agents
in eliminating M. bovis or its effect on
tuberculin responsiveness. Therefore, the use
of INH or other drugs is not recommended.

Swine
M. tuberculosis, M. bovis and M. avium ssp.
avium and M. avium ssp. hominisuis have been
isolated from swine with tuberculous lesions
(236). Outbreaks of M. tuberculosis have been
associated with the feeding of uncooked
garbage from hospitals or residences housing
human cases. Regulations in many developed
countries require that garbage be cooked
before being fed to animals. Enforcement of
these regulations has contributed to the
reduction of disease caused by M. tuberculosis.
Since tuberculous individuals can spread
disease directly to pigs by sputum or body
excretions, they should not be allowed to care
for swine. The lesions in swine infected with
M. tuberculosis are often associated with lymph
nodes of the gastrointestinal tracts. Caseous
lesions are most commonly found in the
mesenteric or submaxillary lymph nodes;
however, microscopic lesions have been
observed in the portal and thoracic nodes and
in the parenchyma of the lungs. The lesions,
characterised by the presence of epithelioid
cells, with occasional giant cells, cannot be
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Horses
Horses can be infected with M. bovis, M. avium
and M. tuberculosis; however, information from
experimental inoculations suggests that horses
are relatively resistant (85). The incidence of
disease in horses is very low in those countries
with national programmes to eradicate
tuberculosis in cattle. The course of disease in
horses appears to be chronic, with the first
signs being loss of body condition, despite a
normal appetite. Lesions are often present in
the liver and mesenteric lymph nodes.
Tubercles are seldom seen in the spleen and
kidneys; however, the spleen may be enlarged
to several times the normal size. Lung lesions
were usually present in M. bovis infections.
Skeletal lesions have been reported.
Microscopically, the granulomas in lymph
nodes and lungs are characterised by
accumulations of epithelioid cells and
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multinucleated giant cells. Mineralisation is
rarely observed; however, necrosis may be
present.
Skin tests conducted in an eyelid or in the
cervical region reveal that some horses without
disease react to tuberculin. There is no
definitive information on the causes of non‐
specific tuberculin sensitivity in the horse. The
diagnosis of tuberculosis in horses should be
based on isolation and identification of the
organism.

Goats
Information on the occurrence of tuberculosis
in goats indicates they are susceptible to
M. bovis, but quite resistant to M. tuberculosis
(235, 237). M. tuberculosis ssp. caprae has been
isolated from goats in Spain (5). In natural and
experimental infections with M. bovis, lesions
are usually present in the lungs and associated
lymph nodes. Tubercles may be present in the
liver and spleen. Histologically, the lesions are
very similar to those observed in cattle. Well‐
defined granulomas are observed and
characterised by the presence of epithelioid
cells and numerous giant cells. AFB are
usually present; however, the number of
organisms varies greatly depending on the
animal.
The diagnosis of tuberculosis in goats is
usually made at necropsy. The tuberculin skin
test appears to be a reliable method for
detecting animals infected with M. bovis.
M. bovis PPD (5 000 TU) can be injected into
the skin in the cervical region. The test sites
should be observed for induration and
swelling at 48 h and 72 h post‐injection. An
increase in skin thickness of 4 mm or more is
considered a positive reaction. A confirmative
diagnosis of M. bovis requires a positive
culture from lesions, because M. avium ssp.
avium and ssp. paratuberculosis cause disease in
this species.

Sheep
Tuberculosis is rare in sheep. M. bovis may
cause lesions similar to those observed in
cattle. Evidence for generalisation of disease
includes the presence of lesions in lungs,
bronchial and mediastinal lymph nodes, as
well as spleen and kidneys (195). The lesions
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are often large and calcified. M. avium also
produces pulmonary lesions in sheep. The
tuberculin skin test is of value in the diagnosis
of tuberculosis in sheep (195, 261). It should be
emphasised that both M. avium and M. bovis
PPD injected at separate sites should be used
because of the susceptibility of sheep to
M. avium ssp. avium.

Dogs
It is generally believed that the susceptibility
of dogs to M. bovis and M. tuberculosis is
similar to that of humans (78, 237). The
occurrence of disease is usually related to
exposure to a tuberculous patient or to M. bovis
infected cattle (225). In naturally occurring
cases, lesions are most often found in the
lungs, liver and kidneys; however, tubercles
may also be observed in the pleura and
peritoneum (85, 93). The lesions are invariably
exudative in type and appear grey in colour.
The absence of calcification has been
considered characteristic of tuberculosis in
dogs; however, exceptions do occur.
Microscopic examination of the lungs may
reveal coalescing lesions with central areas of
caseation.
Numerous
leukocytes
and
macrophages
are
present;
however,
multinucleated giant cells are not usually
observed.
Tuberculin skin tests have been applied but the
efficacy of these tests is unknown. Intradermal
tests can be made on an eyelid, in the cervical
region or in the medial aspect of a rear leg.
M. bovis PPD and M. avium PPD (5 000 TU) can
be used; the injection sites should be examined
at 48 h for the presence of induration,
erythema and necrosis. The diagnosis of
tuberculosis in dogs is usually based on
mycobacteriological examination.

Cats
Cats appear to be very resistant to
M. tuberculosis (85, 235). The incidence of
tuberculosis in cats is related to the presence of
M. bovis infection in cattle and other species
(85, 116). Ingestion of contaminated materials,
including milk and offal from infected cattle or
wildlife, has been incriminated as the most
common source of infection for cats (53, 59, 60,
120, 225). Therefore, the primary site of
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infection is considered to be the alimentary
tract. Transmission of M. bovis through
injection (bites or open wound contamination)
has also been documented (53, 64, 116, 205).
Feral cats have been reported as spill‐over
hosts for M. bovis (45, 53, 169, 205) and other
pathogenic mycobacteria (15, 102), but pose
little likelihood of serving as a reservoir of
disease for other species.

Even
among
household
contacts
of
tuberculosis patients, the risk of infection is
relatively low and is generally reported to be
30% or less (79). In addition, animal and
human studies have demonstrated that
tuberculosis transmission may dramatically
decrease within days to weeks of instituting
effective treatment.

Tuberculin skin tests have been described and
evaluated for detecting infected cats. These can
be of value in epidemiological investigations
on bovine tuberculosis (120). Since cats
infected with M. bovis often develop
pulmonary lesions, they may serve as a
possible source of infection for cattle and other
domestic animals.

In the United States, there had been a steady
5% to 6% annual decline in the case rate of
tuberculosis until 1984 (115). Between 1985 and
1992, however, the annual incidence of
tuberculosis increased by 20% (115). This
increase was concentrated in young, urban,
racial and ethnic minority populations.
Tuberculosis was also found to be prevalent
among the homeless, illicit drug users and
inmates of correctional facilities. In many of
these groups, the rise in tuberculosis was
linked to high rates of HIV infection. A second
trend emerged with increased immigration to
the United States of people from countries
where tuberculosis is prevalent. Before 1986,
foreign‐born inhabitants accounted for 22% of
tuberculosis cases.

Tuberculosis in humans
The sections on tuberculosis diagnosis and
treatment and prevention and control
measures are based on current practices used
in the United States. They may also be relevant
to other low‐incidence, industrialised countries;
however, some details of management are
likely to vary. There are likely to be substantial
differences in practices from those of high‐
burden countries. It is recommended that
readers also review their national tuberculosis
programme and relevant World Health
Organization (WHO) guidelines.

Aetiology and transmission
In humans, tuberculosis is a pulmonary and
systemic disease caused by M. tuberculosis
complex species, predominantly M. tuberculosis.
It is spread from person to person by airborne
transmission of droplet nuclei 1‐5 μm in
diameter. Several factors determine the
probability of transmission, as follows:
 infectiousness of the source patients –
positive sputum smear for AFB or cavities on
chest radiograph being strongly associated
with infectiousness
 host susceptibility of contacts
 duration of exposure
 the environment in which exposure takes
place – small, poorly ventilated space
providing the highest risk (26).
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By 1997, these numbers had increased to 39%
and in 2006 they reached 57% (30). Extensive
national, state, and local control efforts have
led to a new decline of the annual incidence of
tuberculosis since 1992, falling 48% between
1992 and 2006 with 13 779 tuberculosis cases
reported in 2006 (case rate of 4.6 per
100 000 persons) (30). Despite this welcome
decline, the associations of this disease with
conditions such as HIV infection, homeless‐
ness, drug use, foreign birth and racial/ethnic
minority status remain. For example, the
tuberculosis case rate in 2006 for foreign‐born
persons was 9.6 times greater than the rate for
United States‐born persons and for blacks was
8.4 times greater than for whites (30). Of
perhaps even greater concern, the decrease in
overall case rates has slowed in recent years,
from 7.8% per year from 1993 to 2000 to 3.8%
per year from 2000 to 2006 (31).

Drug resistance
Multidrug‐resistant (MDR) tuberculosis is
defined as tuberculosis caused by organisms
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resistant to at least INH and rifampin, the two
drugs that have been most effective for
tuberculosis treatment. MDR tuberculosis is
difficult to treat and generally requires a
minimum of 18 to 24 months of therapy with
second‐line medications (less effective and
more toxic); surgery is also indicated in some
patients (50). The greatest risk factor for the
presence of MDR‐tuberculosis is a history of
prior treatment for tuberculosis (97, 140).
Since 1993, the proportion of patients with
primary MDR tuberculosis decreased from
2.5% to approximately 1.0% (30). The number
of MDR tuberculosis cases in 2006 was 111,
and only 20 of those cases were in United
States‐born people (30). Both in the United
States‐born
and
foreign‐born
patients,
decreases have been seen in the percentage of
cases with primary MDR tuberculosis,
although the decline in the United States‐born
group has been greater. Since 1999, the
percentage of United States‐born persons with
tuberculosis who have MDR tuberculosis has
remained at approximately 0.6%. However, of
the total number of reported primary MDR
tuberculosis cases, the proportion occurring in
foreign‐born persons increased from 26% (105
of 410) in 1993 to 82% (91 of 111) in 2006 (30).
Extensively drug‐resistant (XDR) tuberculosis
is defined as tuberculosis caused by organisms
that are MDR and also resistant to any
fluoroquinolone and at least one second‐line
injectable
drug
(amikacin,
kanamycin,
capreomycin). XDR tuberculosis is very
difficult to treat (the cure rate may be as low as
30‐40%). In the United States, a total of 48 cases
of XDR tuberculosis were reported between
1993 and 2006.

Pathogenesis
Tuberculosis infections occur when susceptible
people inhale droplet nuclei containing
tubercle bacilli and the droplet nuclei reach the
alveoli of the lungs. The tubercle bacilli that
reach the alveoli are ingested by alveolar
macrophages and the majority of these bacilli
are destroyed or inhibited. A small number
multiply intracellularly and are released when
the macrophages die. If alive, these bacilli may
spread through the bloodstream to more
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distant tissues and organs, including areas in
which tuberculosis disease is most likely to
develop: the apexes of the lungs, the kidneys,
the brain and bones and through the lymphatic
system to regional lymph nodes. This process
of dissemination primes the immune system
for systemic responses.
On account of the primed immune system,
extracellular bacilli attract macrophages and
other immunologically active cells. The
immune response kills most of the bacilli and
the remaining bacilli are confined through the
formation of granulomas. At this point, latent
tuberculosis infection (LTBI) has been
established, which may be detected by using
the Mantoux tuberculin skin test or interferon
gamma release assays. Within weeks after
infection, the immune system is usually able to
halt the multiplication of the tubercle bacilli,
preventing further progression.
In some people, the tubercle bacilli overcome
the defences of the immune system and begin
to multiply, resulting in the progression from
LTBI to tuberculosis disease. This process may
occur soon after or many years after infection.
Unless treated, approximately 3‐5% of persons
who have been infected with M. tuberculosis
will develop tuberculosis disease in the first
two years after infection and another 2‐5% will
develop disease sometime later in life. Thus,
approximately 5‐10% of people with normal
immune systems who are infected with
M. tuberculosis will develop tuberculosis
disease at some point in their lives. Immuno‐
compromised persons have a much higher risk
of progression from infection to disease. For
example, HIV‐infected persons not receiving
antiretroviral therapy have an 8% annual risk
of progression (222).

Detection of tuberculosis
The tuberculin skin test (TST) is a major tool
for detecting tuberculosis infection. The TST
(Mantoux method) is performed by the
intracutaneous injection of 5 TU of PPD. The
extent of induration is measured 48 h to 72 h
later. The interpretation of the TST is based on
an individual’s epidemiological risk factors for
tuberculosis infection and progression to
disease. The 2000 American Thoracic Society
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(ATS)/Centers for Disease Control and
Prevention (CDC) guidelines for interpretation
of TST results are as follows:
 5 mm induration is considered positive for:
 individuals with HIV infection or other
comparable immunosuppression (equiva‐
lent to receiving 15 mg or greater of
prednisone for one month or more)
 close contacts with an active tuberculosis
patient
 patients
with a chest radiograph
suggestive of prior tuberculosis (e.g. fibro‐
nodular) disease (also termed ‘inactive
disease’)
 10 mm induration is considered positive for:
 recent immigrants (within the last five
years) from high‐incidence countries
 injection drug users
 residents and employees of high‐risk
congregate facilities, such as nursing
homes, homeless shelters, or prisons
 mycobacterial laboratory personnel
 persons
with
underlying
medical
conditions, such as diabetes, silicosis, end‐
stage renal disease, certain malignancies
and low body weight (loss of at least 10%
of ideal body weight)
 children younger than four years of age
and infants, children, or adolescents
exposed to adults at high risk
 15 mm induration is considered positive for
all others (1).
A positive TST result is considered to indicate
the presence of infection with M. tuberculosis.
In the United States, it is recommended that
persons who test positive receive treatment for
LTBI to prevent progression to disease. Thus,
an intent to test for LTBI should indicate an
intent to treat for LTBI when found.
Consequently, testing should be reserved for
persons at high risk for LTBI or at high risk to
progress to disease, based on their
epidemiological profile.
In a number of situations, the TST is neither
sensitive nor specific for tuberculosis infection.
A positive TST result is a manifestation of
type IV delayed hypersensitivity. Certain
biological conditions, such as viral illnesses
including HIV infection, malignancies and
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other debilitating illness (including advanced
active tuberculosis) and certain medications,
will suppress the type IV response and
T‐lymphocyte function. In addition, proper
application of the TST requires careful
attention to technique and interpretation.
Tuberculin skin testing should be performed
by well‐trained and experienced operators.
False‐positive test findings can occur for a
number of reasons, including cross‐reactions
caused by non‐tuberculous (atypical) myco‐
bacterial infection.
The QuantiFERON®‐TB Gold (QFT‐G, Cellestis
Limited, Carnegie, Victoria, Australia) assay is
an in vitro test that detects the release of
interferon gamma (IFN‐γ) from lymphocytes of
sensitised
persons
when
their
fresh
heparinised whole blood is incubated with
peptide
mixtures
simulating
two
M. tuberculosis proteins called ESAT‐6 and
CFP‐10 (27). A newer version of the test,
QFT‐G In Tube, includes a third antigen,
TB 7.7. QFT‐G and QFT‐G In Tube have been
approved by the United States Food and Drug
Administration (FDA) for use as an in vitro
diagnostic aid in diagnosing M. tuberculosis
infection, including both LTBI and tuberculosis
disease.
Current data indicate that ESAT‐6, CFP‐10 and
TB 7.7 are secreted by all M. tuberculosis and
pathogenic M. bovis strains, but are absent
from all BCG vaccine strains (4). These
proteins are also absent from commonly
encountered non‐tuberculous mycobacteria,
with the exception of M. kansasii, M. szulgai
and M. marinum (4). Thus, QFT‐G offers the
possibility of detecting M. tuberculosis infection
with greater specificity than has been possible
previously with tests that used tuberculin PPD
as the tuberculosis antigen (e.g. TST).
Although the performance of QFT‐G has not
been sufficiently evaluated in selected
populations of interest (e.g. HIV‐infected),
available data indicate that QFT‐G is as
sensitive as TST for detection of tuberculosis
disease and more specific than TST for
detection of LTBI (27, 170). CDC guidelines for
QFT‐G recommend that QFT‐G can be used
instead of TST in all circumstances in which
TST is currently used (27). This includes initial
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and periodic screening of individuals at risk
for tuberculosis infection and screening of
exposed persons in contact investigations.
However, because there are insufficient data
regarding the performance of QFT‐G in certain
clinical situations, the guidelines recommend
following a negative QFT‐G with additional
testing (e.g. TST) or monitoring in such
situations. Examples of clinical scenarios in
which additional testing or monitoring should
be considered include patients with severe
immunosuppression (e.g. HIV infection) who
have had recent exposure to a patient with
tuberculosis and patients about to undergo
treatment with potent tumour necrosis alpha
antagonists.
QFT‐G represents one type of IFN‐γ release
assay. The other type of assay, called Elispot,
enumerates individual lymphocytes producing
IFN‐γ after peripheral blood mononuclear cells
are incubated with similar antigens (76). A
commercial Elispot test (T‐SPOT, Oxford
Immunotech, Oxford) for the diagnosis of
tuberculosis infection was recently approved
by the FDA for use in the United States.

Treatment of latent tuberculosis
The principal preventive tool in the United
States has been treatment of LTBI with INH. In
the 1950s, when INH became available as an
inexpensive, bactericidal and relatively non‐
toxic drug for the treatment of tuberculosis
disease, controlled trials were instituted to
determine its efficacy for the treatment of
LTBI. In more than 70 000 patients, the United
States Public Health Service (USPHS) and
others consistently demonstrated a 60% to 70%
case reduction rate attributable to INH therapy
(79). Follow‐up for as long as 15 years
confirmed the long‐term protection INH
provides against progression to disease.
Concern
regarding
toxicity,
especially
hepatotoxicity, and the need for adherence to a
prolonged course of therapy have limited the
effectiveness of INH therapy as a public health
intervention. Older studies have revealed that
INH‐associated liver injury occurred in about
1% of patients and deaths secondary to INH‐
induced liver injury were reported (132). More
recently, however, public health clinics in
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Seattle and San Diego reported incidences of
hepatotoxicity of 0.1% and 0.3%, respectively,
among over 14 000 patients treated (139, 178).
There were no deaths reported and only one
hospitalisation. Despite the low incidence of
liver injury, completion rates for six months of
therapy were below 65% in both reports.
Both the ATS and CDC recommend that
people with LTBI receive treatment (1).
Clinical monitoring, on a monthly basis at
minimum, is recommended for all patients
receiving
INH.
Routine
transaminase
monitoring should be reserved for individuals
at particular risk for hepatotoxicity, including
those who are pregnant or in the immediate
post‐partum period (first three months) or
those with HIV infection, a history of liver
disease, a history of excess alcohol use, or
other risks for liver disease. The preferred
duration of INH therapy is nine months for all
groups of patients, including those with HIV
infection, those with a chest radiograph
suggestive of prior tuberculosis disease
(inactive tuberculosis) and children (1). Six
months of treatment is considered an
acceptable alternative for immunocompetent
adults without evidence of prior tuberculosis
on chest radiograph, but this shorter duration
is felt to be less effective based on existing
data.
For contacts exposed to INH‐resistant,
rifampin‐susceptible tuberculosis patients,
rifampin (four months duration) can be used
(1). It is important to note that rifampin and a
closely related medication, rifabutin, interact
with protease inhibitors and non‐nucleoside
reverse transcriptase inhibitors that are used to
treat HIV. Consultation with an expert familiar
with both HIV and tuberculosis treatment is
recommended in this situation. For MDR
tuberculosis exposures, some have suggested
the use of pyrazinamide and ethambutol, or
pyrazinamide in combination with a
fluoroquinolone (50). However, data on the
efficacy of these regimens are not available.

Clinical presentation and diagnosis of
tuberculosis
Tuberculosis disease has a wide array of
clinical manifestations, both pulmonary and
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extrapulmonary. Inhaled droplet nuclei of
M. tuberculosis initially lodge in the middle or
lower lung zones where regional ventilation is
greatest, resulting in a local inflammatory
reaction with spread to regional lymph nodes
and subsequent haematogenous dissemin‐
ation. Distant organs, especially the kidneys,
bones, central nervous system, as well as the
lung apices, are seeded, but overt clinical
disease of these areas does not usually ensue.
A low‐grade fever and symptoms of an upper
respiratory illness may also be present. The
chest radiograph may show a small area of
pneumonitis and often hilar and paratracheal
lymphadenopathy. Prominent hilar adeno‐
pathy is frequent in children; it is found less
commonly in adults (134).
This initial infection, termed primary
tuberculosis, resolves spontaneously in most
individuals. Healed lesions appear on chest
radiograph as calcified parenchymal nodules
and are often associated with calcified hilar
lymph nodes. In a small percentage of
individuals, the initial infection progresses and
can manifest as follows:
 rupture of subpleural infectious foci into the
pleural space, resulting in tuberculous
pleuritis
 extensive caseous pneumonia
 enlargement of tuberculous lymph nodes,
causing bronchial obstruction (collapse‐
consolidation lesions)
 rupture of a tuberculous focus into a
bronchus, leading to extensive endo‐
bronchial spread throughout one or both
lungs
 rupture of a tuberculous focus into a
pulmonary
blood
vessel
with
haematogenous spread leading to acute
disseminated disease (148).
Tuberculosis can reactivate months to years
after containment of the primary infection. The
factors causing reactivation of lesions are
poorly understood. Certain conditions increase
the likelihood of progression of LTBI to
disease, including malnutrition, alcoholism,
poorly controlled diabetes mellitus, silicosis,
immunosuppression (by disease processes or
drugs), the post‐partum period, gastrectomy,
chronic haemodialysis and jejunoileal bypass
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surgery (1). In most patients, however, no
predisposing factor can be identified.
Radiographically, reactivation or post‐primary
pulmonary tuberculosis usually presents as an
infiltrate in the apical and posterior segments
of the upper lobes (148). Patients can be
entirely asymptomatic or have non‐specific
symptoms of chronic respiratory infection
(e.g. fever, weight loss, productive cough and
haemoptysis). Chest radiographs may reveal
somewhat nondescript fibronodular or fluffy
alveolar‐filling process in the upper lung
fields, but frequently show cavity formation,
fibrosis with volume loss, or both. New
haematogenous dissemination and extra‐
pulmonary disease may follow pulmonary
reactivation.
The definitive diagnosis of pulmonary
tuberculosis depends on obtaining a positive
culture from infected secretions or tissues. If
cultures are negative or obtaining a culture is
not possible, presumptive diagnosis can be
made from clinical inference and therapeutic
trials. The TST provides information as to
whether tuberculous infection is present, but
does not distinguish between disease and
LTBI. False‐negative TST results are common
in immunosuppressed patients (advanced
tuberculosis itself being sufficiently immuno‐
suppressive). A typical chest radiograph is
helpful, but non‐specific: a variety of non‐
tuberculous processes can have a similar
appearance.
Spontaneous or aerosol‐induced sputum
sampling (at least three specimens) is the
method
of
choice
for
bacteriological
assessment. Initially, the specimens are stained
by the Ziehl‐Neelsen or fluorescent techniques
for AFB. Specimens should be cultured for
mycobacteria. Cultures are essential for the
following reasons:
 smears alone will miss up to 50% of active
tuberculosis cases
 mycobacteria other than M. tuberculosis can
produce positive smears
 cultures are necessary for drug susceptibility
testing.
The newest laboratory tools for the diagnosis
of tuberculosis are nucleic acid amplification
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(NAA) tests performed on direct specimens
(i.e. without the need for growing cultures)
(24). Two commercially available NAA tests
have been approved by the United States FDA
for use on AFB smear‐positive respiratory
specimens, namely: the PCR and transcription‐
mediated amplification. NAA tests can be
performed in several hours. The combination
of a positive AFB smear and positive NAA test
is essentially diagnostic of active tuberculosis.
Negative NAA tests in the face of positive AFB
smear suggests that patients have infection
with non‐tuberculous mycobacteria. NAA tests
are also approximately 25‐30% more sensitive
than the AFB smear and can be of use when
smears are negative and the clinical suspicion
for tuberculosis remains moderate or high.
Transcription‐mediated amplification has also
been approved by the FDA for use on AFB
smear‐negative specimens. There is less
experience with the use of NAA tests for non‐
respiratory specimens. Several studies suggest
they can be useful for the diagnosis of
extrapulmonary tuberculosis, especially for
meningitis. The finding of a positive NAA test
does not obviate the need for cultures, as NAA
tests do not give any information about drug
susceptibilities.
Extrapulmonary tuberculosis can occur with or
without
concurrent
active
pulmonary
tuberculosis. Most frequently, the pathogenesis
is that of recrudescence of a previously
quiescent haematogenous lesion. However,
upper airway and laryngeal disease, lymphatic
tuberculosis and pleural or pericardial
tuberculosis commonly arise by extension
from contiguous structures. Gastrointestinal
tuberculosis
can
follow
ingestion
of
expectorated infectious sputum or ingestion of
unpasteurised dairy products from cattle
infected with M. bovis (a rare cause of human
tuberculosis).
Tuberculosis in HIV‐infected patients often
presents differently from that observed in
immunocompetent patients (107). Atypical
features of tuberculosis found in HIV‐infected
patients include the following:
 higher frequency of negative TSTs (61% vs
10%)
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 higher frequency of extrapulmonary sites
(60% vs 28%)
 higher frequency of diffuse or miliary
infiltrates (60% vs 32%)
 higher frequency of hilar adenopathy (20%
vs <5%)
 higher
frequency
of
normal
chest
radiographs with pulmonary involvement
(15% versus <1%)
 lower frequency of focal infiltrates (35% vs
68%)
 lower frequency of cavities (18% vs 67%).
Atypical clinical and radiographic features of
tuberculosis in HIV patients are more likely to
be seen in those patients with lower CD4
counts, especially below 200 (117). Patients
infected with HIV are much more likely to
develop rapidly progressive, sometimes fatal
disease.

Treatment of tuberculosis
Drugs used to treat tuberculosis can be
divided into first‐line and second‐line agents.
The first‐line (i.e. most effective and least toxic)
drugs consist of INH, rifampin, pyrazinamide
and ethambutol (2). INH and rifampin are very
effective bactericidal drugs. The principal
adverse reactions of INH include hepatitis and
neuritis. The major side‐effects of rifampin are
hepatotoxicity and hypersensitivity reactions
(226). Some evidence suggests that the
combination of rifampin and INH can be
associated with a greater incidence of liver
injury than with either drug alone.
Hypersensitivity reactions, including a flu‐like
syndrome, thrombo‐cytopaenia and, rarely,
acute renal failure, have been reported, usually
occurring with intermittent rifampin therapy.
Rifampin increases hepatic metabolism of
some drugs, causing important drug
interactions. Pyrazinamide is used for the first
two months in many treatment regimens. Its
principal side‐effects are hepatotoxicity and
hyperuricemia; the latter rarely leads to gout
or renal failure. Ethambutol is a bacteriostatic
agent that has been in general use for over
three decades. A dose of 25 mg/kg daily is
used for two to three months and then
decreased to 15 mg/kg. Retrobulbar optic
neuritis has occasionally complicated therapy

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

155

Tuberculosis: a re‐emerging disease in animals and humans

with doses in excess of 20 mg/kg for prolonged
periods, but is rarely seen when using
15 mg/kg.
Second‐line medications are generally reserved
for therapy of drug‐resistant disease or for
patients intolerant of first‐line medications.
Fluoroquinolones are among the latest
additions to the anti‐tuberculous armament‐
arium. They are generally well tolerated and
several have good in vitro activity against
M. tuberculosis. Levofloxacin and moxifloxacin
are the first choices of medications in this class
because they have superior in vitro activity
compared to other older fluoroquinolones and
they also have a good safety profile. Rare
gastrointestinal side‐effects, such as nausea
and bloating, and neurological side effects,
including dizziness, insomnia, tremulousness
and headaches, may occur with fluoro‐
quinolones. Several aminoglycoside antibiotics
are of proven efficacy in the therapy of
tuberculosis. Unfortunately, they all require
intramuscular or intravenous administration
and have a high incidence of serious side‐
effects.
Streptomycin, the first drug available for
tuberculosis therapy, is still used occasionally;
however, its value is limited by dose‐related
renal and eighth cranial nerve toxicities and an
increasing incidence of drug resistance. Other
aminoglycosides, such as capreomycin,
kanamycin and amikacin, have similar
toxicities and may be slightly less effective.
PAS, ethionamide and cycloserine are oral
preparations that are usually used only in
MDR tuberculosis. PAS and ethionamide can
cause severe gastrointestinal distress, whereas
cycloserine is associated with personality
changes, depression, frank psychoses and, in
high doses, seizures.
For patients with INH‐ and rifampin‐
susceptible pulmonary tuberculosis, standard
treatment is divided into an initial phase of
two months (8 weeks) followed by a
continuation phase of four months (18 weeks)
(2). Given the relatively high rate of INH
resistance in adults, their initial‐phase
treatment should consist of INH, rifampin,
pyrazinamide and ethambutol for two months.
For children, ethambutol is usually not needed
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unless there is particular concern for INH
resistance or the child has a clinical pattern
usually seen in adults (i.e. upper lobe infiltra‐
tion, cavity formation). Once susceptibility
results become available, ethambutol may be
discontinued (or omitted if drug susceptibility
results are known prior to beginning
treatment) if the organism is susceptible to
INH and rifampin.
If pyrazinamide cannot be included in the
initial phase of treatment, or if the isolate is
resistant to pyrazinamide alone, the initial
phase should consist of INH, rifampin and
ethambutol (at least until drug susceptibility
results are known) (see above) administered
daily for two months. Situations where
pyrazinamide may be withheld include severe
liver disease, gout and pregnancy. The initial
phase may be given daily for eight weeks,
daily for two weeks and then twice weekly for
six weeks, or three times weekly for eight
weeks. Twice weekly therapy is never
recommended for HIV‐infected patients with
CD4 counts below 100 in the initial or
continuation phase of tuberculosis treatment
(see below) (29).
The standard continuation phase therapy for
tuberculosis susceptible to INH and rifampin
consists of INH and rifampin (2). Treatment
may be given daily, twice weekly (except in
HIV‐infected patients and when the CD4 count
is below 100), or three times weekly. For HIV‐
seronegative patients with non‐cavitary
pulmonary tuberculosis and negative sputum‐
smear results at the completion of two months
of treatment, an alternative continuation phase
treatment is INH and rifapentine (a long‐acting
analogue of rifampin) administered once
weekly. The duration of the continuation
phase is four months (six months total
treatment) for most patients with drug‐
susceptible tuberculosis. However, patients
that did not have pyrazinamide included in
their initial phase should have their
continuation phase extended to seven months
(nine months total treatment). In addition,
patients with positive sputum cultures after
two months of therapy and cavities on chest
radiograph are more likely to fail treatment or
relapse. Therefore, such patients should also
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have their continuation phase extended to
seven months as should patients being treated
with once weekly INH and rifapentine with
positive sputum cultures after two months of
treatment regardless of chest radiographic
findings.
Since the 1990s, the use of directly observed
therapy (DOT) by local health departments has
become a major tool in tuberculosis control.
With DOT, some or all doses of medication are
taken in the presence of a nurse or other
ancillary healthcare worker. This can be done
by having the patient come to the clinic or by
sending an outreach worker to the patient’s
home. Use of DOT minimises the risk of
treatment failure and acquired drug resistance
due to non‐adherence.
To monitor response to therapy, sputum
cultures should be collected every month until
cultures are negative for two consecutive
months. Since over 90% of patients have
negative sputum cultures after three months of
treatment, any individual with a positive
sputum culture at this point should be
carefully evaluated to try to identify the
aetiology of this delayed response to therapy.
A patient with a positive sputum culture after
four months of treatment is considered a
treatment failure. Possible reasons for
treatment failure include non‐adherence and
medication malabsorption. In addition to
addressing the reasons for treatment failure,
repeat susceptibility testing should be
performed to assess for acquired drug
resistance. If the treatment regimen is going to
be modified, at least three new drugs to which
the patient’s organism would be expected to be
susceptible should be added. A cardinal rule of
tuberculosis therapy is that a single drug
should never be added to a failing regimen.
Patients infected with organisms that are
resistant to INH, rifampin, or both, require
modifications in their drug regimens (2, 50).
For tuberculosis that is INH‐resistant (but
rifampin‐susceptible), the recommended daily
regimen is rifampin, ethambutol and
pyrazinamide for six months. A fluoro‐
quinolone may be added to strengthen this
regimen in patients with extensive disease. For
tuberculosis resistant to rifampin (but INH‐

© IZS A&M 2009

susceptible), the recommended therapy is
INH, ethambutol and a fluoroquinolone for 12
to 18 months with pyrazinamide added for the
first two months. Tuberculosis that is resistant
to at least INH and rifampin is termed MDR.
Treatment of MDR tuberculosis is often
complex and should be performed in
consultation with a tuberculosis expert. MDR
tuberculosis should be treated with four to six
medications to which the organism is
susceptible. Therapy should continue for at
least 18 to 24 months. Surgical resection of
heavily diseased areas of the lungs is
sometimes used as an adjunctive therapy for
MDR tuberculosis and should be considered in
suitable candidates.
Chemotherapy for extrapulmonary tuber‐
culosis does not differ in principle from that
for pulmonary tuberculosis (2). The duration
of therapy is the same as for pulmonary
disease, with the exception of:
 meningitis, for which nine to 12 months of
treatment is recommended
 bone and joint disease, for which some
experts recommend extending treatment to
nine months.
Corticosteroids should be used routinely in the
treatment
of
central nervous system
tuberculosis,
including
meningitis
and
pericarditis, but are not recommended as an
adjunct for treatment of other forms of
tuberculosis.
Tuberculosis treatment of HIV‐infected
patients is similar to that of HIV‐negative
patients, although there are several differences
(29). On account of the complex drug
interactions between many antiretroviral
medications and rifamycins, it is strongly
recommended that tuberculosis treatment of
patients on such drugs be carried out in
consultation with a clinical HIV expert. The
combination of once weekly INH and
rifapentine should never be used in HIV‐
infected individuals as this has resulted in high
rates of treatment failure and relapse
associated with acquired rifampin resistance.
Biweekly therapy should not be used in HIV‐
infected patients with CD4 counts below 100
for the same reason. Currently, the combin‐
ation of efavirenz‐based antiretroviral therapy
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(efavirenz plus two nucleosides) and rifampin‐
based tuberculosis treatment, at their standard
doses is the preferred treatment for HIV‐
related tuberculosis. For patients unable to
take non‐nucleoside reverse transcriptase
inhibitor‐based antiretroviral therapy, the
combination of rifabutin (as a substitute for
rifampin) with protease inhibitor‐based
antiretroviral therapy is the preferred form of
treatment.
Temporary exacerbation of tuberculosis
symptoms and lesions can occur in patients
with HIV who are taking antiretroviral
therapy. This phenomenon, known as the
immune
reconstitution
inflammatory
syndrome or the paradoxical reaction, has
been attributed to recovery of the delayed
hypersensitivity response in these patients and
increased exposure to tuberculosis antigens
following the initiation of bactericidal anti‐
tuberculous therapy. In general, modifications
of tuberculosis therapy and antiretroviral
therapy are not necessary, and a short course
of corticosteroids may ameliorate symptoms
associated with this reaction if it is severe.
Adverse drug reactions can occur at any time
during treatment. Often difficult to diagnose,
they can be confused with manifestations of
tuberculosis or other concurrent illnesses.
Sometimes drug reactions are relatively mild
so that stopping therapy is not warranted.
Specific reactions can be handled by
discontinuing the suspect drug. Often drugs
have overlapping toxicity and reactions are
non‐specific (e.g. fever, rash, jaundice). In such
cases, all drugs should be stopped for a brief
period (e.g. one week) and then reintroduced
singly, the least likely offender first. Some
clinicians re‐initiate drugs at low doses,
whereas others resume full‐dose therapy. If a
reaction appears a second time, then another
drug may need to be substituted. (One drug
can be added to a successful regimen as long
as the entire regimen is adequate.)
All patients receiving tuberculosis treatment
should be counselled and tested for HIV
infection. Patients with risk factors for
hepatitis B or C should be tested for these
viruses.
Baseline
serum
transaminase,
bilirubin, alkaline phosphatise, creatinine
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levels and a platelet count should be measured
for all adults. Visual acuity and colour testing
should be performed on all patients receiving
ethambutol. Monitoring recommendations for
individual second‐line drugs can be found in
the ATS/CDC/Infectious Diseases Society of
America 2003 Treatment of Tuberculosis
statement (2).
Surgery is rarely necessary except in selected
cases of MDR tuberculosis and for
complications of tuberculosis such as:
 emergency
treatment
of
massive
haemoptysis
 therapy of bronchopleural fistulas
 drainage of true (purulent) tuberculous
emphysemas
 for relief of mechanical problems in skeletal
tuberculosis, such as spinal stabilisation
procedures in selected individuals with
Pott’s disease.

Human tuberculosis in the United
States caused by Mycobacterium bovis
While human M. bovis disease is rare in the
United States overall, it appears to be more
common in certain geographic regions of the
country. Approximately 1% of human
tuberculosis in the United States is caused by
M. bovis, but from 1994‐2000, 7% of culture‐
positive tuberculosis patients in San Diego had
disease caused by M. bovis (113, 138). A large
majority (90%) of these patients were Hispanic
persons born in the United States or Mexico,
and most had extrapulmonary disease. A
study of paediatric tuberculosis in the San
Diego region revealed that for many children
infected with tuberculosis the only risk factor
was ingestion of unpasteurised dairy products
from Mexico (13). These findings have
implicated dairy products from Mexican cattle
herds as the major source of M. bovis infection
for patients in San Diego. Ultimately,
eradication of human M. bovis disease in this
setting will require eradication of the
organisms in the infected dairy herds by
culling. In the short term, more extensive
efforts at educating the public about the
dangers of consuming raw dairy products are
needed.
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Compared to transmission from cattle to
humans, the role of human‐to‐human airborne
transmission in the spread of M. bovis is
controversial. The predominant view has been
that human‐to‐human transmission is a rare
event and is only likely to occur in populations
that are particularly susceptible to tuberculosis
(e.g. HIV‐infected persons) (14, 107, 208). Prior
reports of clusters of cases with social and
molecular epidemiological links and evidence
from contact investigations of patients with
pulmonary M. bovis have suggested that
human‐to‐human transmission does occur,
even in non‐immunosuppressed persons. A
recent report by Evans et al. is the best
documented instance of multiple events of
likely human‐to‐human transmission (75).
Based on these findings, it seems prudent from
a public health standpoint, to treat pulmonary
M. bovis patients in the same manner as
pulmonary M. tuberculosis patients.
Respiratory precautions, as determined by
local health department policies and
procedures, should be instituted for all
patients with potentially contagious M. bovis.
Directly observed therapy is the preferred
method of treatment for tuberculosis patients,
regardless of whether the infecting organism is
M. tuberculosis or M. bovis. Contact investig‐
ation should be conducted in the same manner
for M. bovis and M. tuberculosis patients, and
priority of the contact investigation should be
assigned based on patient characteristics, such
as sputum AFB smear results or cavity on
chest radiograph, not the species of
tuberculosis infecting the patients. Finally, it is
important that all tuberculosis patients be
offered HIV counselling and testing.
While controlled clinical trials have not been
performed to determine the efficacy of
treatment for M. bovis disease in humans,
programmatic data suggest that treatment
outcomes are similar to those found for
treatment of M. tuberculosis disease when
standard
regimens,
based
on
drug‐
susceptibility testing, are used (e.g. nine
months of INH and rifampin for M. bovis that
is susceptible to both drugs) (141). As no
diagnostic test exists that can distinguish
M. tuberculosis from M. bovis when the
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infection is latent, the relative efficacy of LTBI
treatment for M. bovis cannot be evaluated.
Nevertheless, it seems reasonable to treat
persons with LTBI where M. bovis is the
suspected cause, especially since M. tuberculosis
infection cannot be excluded as a possibility
(77).

Tuberculosis in Latin America and
the Caribbean
Tuberculosis continues to be a major cause of
illness and death worldwide. According to the
WHO, there were an estimated 9.2 million new
cases of tuberculosis in 2006 (139 per
100 000 population), 8% of them HIV+ and
more than 5% MDR. Distribution of
tuberculosis shows enormous differences
according to the region of the world. Most of
the 22 high‐burden countries that collectively
account for 80% of tuberculosis cases are
situated in Africa and one (Brazil) in the
American region. The number of estimated
tuberculosis cases in the Americas was 330 724
in 2006 (37/100 000), representing only 3.6% of
the total worldwide. Of these, 4.9%
corresponded to the United States, Canada,
Cuba and Jamaica, where incidence rates were
4, 5, 9 and 7/100 000, respectively. On the other
hand, the highest incidence rates in the region
were found in Haiti, Bolivia and Peru, that
attained, respectively, 299, 198 and 162 per
100 000 (Table I). However, tuberculosis
morbidity globally decreased in the region
between 1990 and 2006 from 65 to 37 per
100 000 population (280).
While a majority of the tuberculosis cases are
due to M. tuberculosis, the real incidence of
M. bovis in humans continues to be roughly
underestimated or even ignored for most of
the countries in the Latin American and the
Caribbean region.
There is a great heterogeneity in terms of
geographic surface, human and cattle
population, as well as in the development of
cattle breeding and dairy industry among
countries of this region (83, 280). Two of the
main meat exporting countries in the world,
Brazil and Argentina, are situated in South
America. Their cattle populations are
respectively 189 and 51 million head (Table II).
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Table I
Estimated burden of tuberculosis and percentage of positive human immunodeficiency virus cases in
thirteen countries of Latin America and the Caribbean, 2006
Country

No. cases
(tuberculosis incidence
per 100 000, all forms)

No. of smear-positive
cases (tuberculosis
incidence per 100 000)

15 231 (39)
18 562 (198)
93 933 (50)
2 417 (15)
20 522 (45)
1 018 (9)
8 534 (89)
16 958 (128)
22 473 (21)
1 463 (45)
44 815 (162)
910 (27)
11 271 (41)

6 787 (17)
8 344 (89)
59 371 (31)
1 085 (7)
9 192 (20)
458 (4)
3 812 (40)
7 612 (58)
10 087 (10)
638 (19)
20 076 (73)
397 (12)
5 005 (18)

Argentina
Bolivia
Brazil
Chile
Colombia
Cuba
Dominican Republic
Ecuador
Mexico
Panama
Peru
Uruguay
Venezuela

Human immunodeficiency
virus prevalence in incident
cases (%)
4.0
0.5
13.0
1.1
2.1
0.3
3.3
1.1
1.1
14.0
2.0
14.0
5.8

Source: de Kantor et al. (56)

consumption imported from Mexico, due to
the detected tuberculosis infection in these
cattle, supported the decision of controlling
and eradicating BTB from beef cattle in this
country (66).

The economic relevance that meat and dairy
industries play stimulated the political
decision from national authorities, to
promoting bovine tuberculosis (BTB) control
programmes in order to eradicate BTB, in
addition to other cattle diseases that limit the
economic benefits obtained by exporting meat
and dairy products. In a similar way, sanitary
restrictions applied by the United States to the
entrance of cattle destined for public

Globally, about 70% of cattle bred in Latin
America are held in areas with relatively high
prevalence of BTB infection and only 17% in
areas virtually free of BTB. In general, official
reports on the epidemiological situation of

Table II
Total bovine population in thirteen Latin American and Caribbean countries, estimated percentages of
bovine tuberculosis infection in dairy cattle, and confirmed Mycobacterium bovis isolates from humans,
2000-2006
Country

Bovine population
(millions)

Percentage of PPD
reactors in dairy cattle

Mycobacterium bovis
isolates from humans

Argentina
Bolivia
Brazil
Chile
Colombia
Cuba
Dominican Republic
Ecuador
Mexico
Panama
Peru
Uruguay
Venezuela

51.0
7.1
189.0
2.8
25.0
2.4
1.9
3.6
26.0
1.2
7.5
11.7
13.5

≥1.0
≥1.0
0.5-1.0
0.5-1.0
0.1-1.0
<0.1
0.1-1.0
≥1.0
0.1-1.0
<0.1
0.5-1.0
<0.1
<0.1

Yes
No
Yes
No
No
No
No
Yes
Yes
No
No
No
Yes

PPD purified protein derivative
Source: de 'Kantor & Ritacco (55), de Kantor et al. (56), de Kantor & Torres (57), Food and Agriculture Organization (83), Ritacco et al.
(212), World Organisation for Animal Health (280)
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cattle infection are only limited to certain
areas, and do not have national coverage (54,
211). Consequently, information given in this
review is based on regional surveys and other
field research work, and on notifications made
by the countries to the World Organisation for
Animal Health (Office International des
Épizooties: OIE) and Food and Agriculture
Organization (FAO) (83, 280).
Even though BTB infection continues to be
prevalent in most of these countries and affects
dairy cattle in particular, there has been a
sustained improvement in control activities
over the last decade. Milk pasteurisation, as
well as sanitary controls and surveillance in
the dairy industry, have limited the risk of
infection by the digestive route in the general
population. However, at the same time, those
who work in close contact with cattle, in
breeding and milk producing establishments,
or in slaughterhouses, continue to be exposed
to acquiring infection by the respiratory route
(56).
Currently, most countries in Latin America
and the Caribbean have public health
laboratory networks, with facilities to perform
diagnostic techniques for tuberculosis, from
smear examination by Ziehl‐Neelsen, to
culture and drug susceptibility testing (DST) of
the mycobacterial isolates. In their reference
laboratories, molecular and phenotypical
identification tests are also performed. In the
last decade, an outstanding development of
molecular methods has taken place in the
region, where these techniques were applied in
cooperation
with
tuberculosis
control
programmes, in public and in animal health, to
explore epidemiological issues.
The certainty in the diagnosis of human or
bovine tuberculosis is only achieved by
isolating the bacillus and identifying the
species, on the bases of the corresponding
phenotypic and molecular tests. Recently, it
has been demonstrated that a mutation in the
glycerol‐kinase gene of the M. bovis genome
inactivated this enzyme and, consequently,
M. bovis was enabled to metabolise glycerol
(125). For this reason, M. bovis needs pyruvate
as a C source to grow, especially on egg
containing culture media. Thus, only if
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pyruvate is added to these media in place of
glycerol, can M. bovis be cultured with ease.
Löwenstein Jensen and Ogawa are the glycerol
containing egg media usually employed by the
laboratories in this region, mainly due to their
relatively low cost and robustness (190).
M. bovis rarely grows there and, if it does, it
takes more than two months to develop
dysgonic colonies that are small and very
difficult to detect. For this reason, only in
studies where egg media containing pyruvate,
or other rich semi‐synthetic liquid media
systems, are employed for culturing myco‐
bacteria, can reliable information on the
relevance of BTB in humans be obtained.
Recently, in several national reference
laboratories, BACTEC 12B and BBL MGIT
960 liquid media were introduced for the
recovery of mycobacteria. Positive identific‐
ation of M. bovis can be performed by genetic
tests (i.e. AccuProbe M. tuberculosis complex
culture identification test kit, Gen‐Probe, San
Diego, California) and by phenotypic/
biochemical reactions for niacin and nitrate
which are negative for M. bovis (56, 112, 190).
Table I shows that almost half the number of
tuberculosis cases diagnosed in the region
were confirmed bacteriologically. However, in
most of these, confirmation was only made by
the microscopic smear examination. This
technique, which is rapid, economical and
relatively specific, enables the detection of
highly infectious pulmonary cases that are the
sources of infection in the community which
can then be treated until cure. However, as is
well known, mycobacterial species cannot be
differentiated by acid‐fast staining, which
means the information on M. bovis cases
remains unknown. Differentiating M. bovis
from M. tuberculosis is not considered a public
health priority in the countries of Latin
America and the Caribbean because the
current standard treatment with an initial
phase
consisting
of
INH,
rifampin,
pyrazinamide and ethambutol, is quite
effective against both infecting agents. Even
though bovine tubercle bacilli are inherently
resistant to pyrazinamide, they are sterilised
by the combined action of the remaining three
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drugs, except in case of strains already
resistant to these drugs (278).

and acquired drug resistance due to non‐
adherence (278).

According to the laboratory standards for
tuberculosis control programmes, culture is
usually reserved for the diagnosis of extra‐
pulmonary tuberculosis cases in children and
the suspected pulmonary tuberculosis‐
negative children to microscopy examination.
The use of this method is also recommended
for HIV co‐infected or suspected MDR‐
tuberculosis, so that the DST can be performed
on positive cultures (190). In 2005 and 2006, the
total number of tuberculosis microscopy
laboratory services (level I, classically ‘one
microscope lab’) in the Americas (excluding
the United States and Canada) as reported to
the WHO, was 12 554, while in 1908 culture
techniques of other laboratories were also
applied (‘complexity level II’). In only
100 other laboratories (level III, maximum
complexity), DST and species identification
tests were performed (279). As a comparison,
the United States reported laboratory findings
from a total of 1 657 laboratories and Canada
10. All of these laboratories have adequate
facilities for smear, culture, DST and species
identification. Uruguay reported only one
laboratory with a similar capacity and
complexity of those in United States and
Canada.

Taking into consideration these limitations in
the laboratory diagnostic facilities, the
proportion of M. bovis cases to the total of
human tuberculosis reported, can only be
determined from specially designed studies in
which, during a period (one to two years at
least), all specimens submitted to tuberculosis
diagnosis in one or more laboratories, are
cultured on the appropriate media and the
isolated mycobacteria are analysed to
differentiate M. bovis from M .tuberculosis and
other Mycobacterium species. When this type of
information is available, correlation between
the prevalence of M. bovis infection in humans
and its evolution in time in relation to that of
the infection in cattle for a particular region or
country can be analysed (56).

In the remaining countries, the proportion of
level III to the basic level I, was approximately
1:126. These differences clearly explain the
difficulties to obtain information on the
number of tuberculosis cases caused by
M. bovis infection. For similar reasons, DST
cannot be offered for every new tuberculosis
case diagnosed. Tuberculosis chemotherapy
regimens applied in these countries are based
on epidemiological estimates obtained from
periodical countrywide surveys. In these
surveys, the prevalence of drug resistance and
MDR is investigated on statistically designed
samples of the populations of patients (278).
Currently, a standard chemotherapy regimen
with four drugs applied in the first two
months, followed by two drugs in the
continuation phase (two months) has been
adopted in most of these countries. The DOT
strategy minimises the risk of treatment failure

162

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

Vol. 45 (1), Vet Ital

Tuberculosis at a global level
Tuberculosis has affected humans since
prehistoric times. It has been identified in
ancient human remains from virtually every
region on Earth. The characterisation of the full
genome sequence of M. tuberculosis (41) has
laid the basis for significant advances in the
understanding of the organisms. Previous
understanding of the origin of tuberculosis
postulated that it began as a zoonosis at the
time that humans domesticated and lived
closely with cattle, although molecular genetic
studies (18) have suggested that this may not
have been the case, and that human
tuberculosis
(M. tuberculosis) may
have
predated tuberculosis in animals (M. bovis).
The micro‐organisms have spread to all groups
in the human population and constitute a
major threat to human health globally. Over
the past decade, over 8 million new cases of
tuberculosis are thought to occur each year.
Although the disease is relatively rare
(affecting less than 1 person in every 1 000 per
year), it has a major impact on the economic
productivity of the population because it is a
chronic disease with a relatively high case
fatality rate if left untreated (50% of those
affected will die of the disease) and because
the target group affected is primarily persons
aged between 15 and 49 years of age, the
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The disease is not uniformly distributed in the
global population. While in some countries
(the United States, Canada and the Nordic
countries), the case rate is less than 5 cases per
million in the population, 80% of all cases
occur in just 22 countries, primarily in sub‐
Saharan Africa and Asia. There is a close
association between poverty and risk of
tuberculosis both in the global distribution and
within industrialised countries where the few
cases that occur are found in poor,
marginalised and vulnerable groups in the
population. Indeed, even in industrialised
countries, where the case rate is now extremely
low, the risk of developing disease among the
marginalised and vulnerable groups is almost
as high as in poor countries where tuberculosis
is much more common (70).
Progress in the global control of tuberculosis
has been challenged by several important
factors. The first is the close association of
tuberculosis with poverty. This is largely
explained by a much higher risk of exposure
due to poor ventilation and housing, more
crowded living conditions associated with
higher numbers of contagious patients in the
community. While some remain optimistic that
substantial progress is being made in the fight
against poverty, there are many reasons to
believe that the distribution of wealth is less
equal today than it was even two decades ago.
The trend in inequality in wealth distribution
will certainly determine the trend in the
tuberculosis burden.
A second major factor that mitigates against
success in conquering tuberculosis globally is
the close association between tuberculosis and
the epidemic of HIV. This immediately
increases the number of patients who develop
tuberculosis (rising from a lifetime risk of one
in ten in those who are immune competent to a
risk of that size within a single year among
those living with HIV).
This larger number of cases of tuberculosis
leads, secondarily, to an increased risk of
infecting other members of the society and a
subsequent escalation in the number of cases
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from this source as well. This has led to a
geometric rise in the numbers of patients
affected by tuberculosis in many countries in
southern Africa, such that the case rates of
tuberculosis are now reaching historic highs.
This led the WHO in 2005 to declare
tuberculosis an emergency within the region.
There are early, but not conclusive, indications
that the rising impact of HIV on tuberculosis
may be reaching a peak, although it can be
expected that the numbers of tuberculosis
cases will continue to rise annually for the near
future, with the result that sub‐Saharan Africa
will contribute increasingly to the total global
burden of disease, with its economic
consequences
in
communities
already
struggling to survive. The third challenge to
global efforts to contain this disease is the
emergence of drug resistance. Resistance to
tuberculosis medications is present in some of
every large population of micro‐organisms due
to genetic mutations in the organisms.
Such bacilli may infect others and the disease
they cause will be resistant to this medicine
(primary resistance). If the sequence is
repeated, resistance develops to further
medication. M. tuberculosis (XDR‐TB) and
XDR‐TB more so, is a form of the disease that
is very difficult to cure. The WHO estimates
that there are just under half a million MDR‐
TB cases each year in the world (279).

Bovine tuberculosis in several Latin
American and Caribbean countries
Argentina
The National Programme of BTB Control and
Eradication (Servicio Nacional de Sanidad y
Calidad
Agroalimentaria:
SENASA)
was
launched in 1998. Its main goal is the
eradication of BTB in dairy cattle. Its activities
are coordinated with the dairy industry,
university veterinary schools, technological‐
agricultural institutions (Instituto Nacional de
Tecnología Agropecuaria: INTA) and the
veterinary associations in the country. By 2006,
the number of dairy herds officially certified as
being tuberculosis‐free by SENASA was 6 739
of the national total of 12 000, with
approximately 2 million milk producing cows.
Of the 1.8 million bovines in the tuberculosis‐
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glycerol containing egg media. A pyruvate egg
medium (Stonebrink) has been introduced for
experimental trials, but no M. bovis case has
been reported (M. Camacho, personal comm‐
unication, 2006).

free herds, 90% are dairy cows. These are
located in the provinces of Buenos Aires, Entre
Ríos, Santa Fe, La Pampa and Córdoba. A total
of 6 193 private accredited veterinarians
guarantee a good coverage in the control and
surveillance services in these provinces.
Argentina exports meat and dairy products to
155 countries. Dairy products must show a
certified origin from officially tuberculosis‐free
herds.

Brazil
According to surveys and official reports, the
average prevalence of BTB infection in cattle is
1.3%. It is estimated that cattle in 5% of herds
are infected, but the percentage could be as
high as 15% in large dairy herds. Bovine
tuberculosis has been confirmed bacteriolog‐
ically in cattle and swine samples. The
National Programme for BTB Eradication was
launched in 2001. A standardised cervical
tuberculin test with bovine PPD has been
adopted countrywide (166). Between 1996 and
2006, only three human M. bovis cases were
confirmed
from
over
7 000 specimens
examined
by
bacteriological
methods.
According to this information, the current
M. bovis prevalence among tuberculosis cases
would be below 0.05% (56).

Between 1969 and 2006, an annual average of
10 million cattle were slaughtered and
submitted to veterinary inspection. The
percentage of animals that suffered partial or
total condemnation for tuberculosis decreased
from 6.7% to 1.0% in this period (57, 255).
Human tuberculosis due to M. bovis has been
systematically investigated in several reference
laboratories. Figures from Buenos Aires and
Santa Fe provinces show a tendency to decline
in time; this can be related to the improvement
in food hygiene, pasteurisation of milk and
dairy products, and in the progress obtained in
the BTB control activities led by SENASA (54,
57, 67, 189, 211) (Table III).

Chile
Bovine tuberculosis infection affects 56% of
cattle herds located in Regions V and
Metropolitan (Santiago), but only 5.1% in
Regions VIII to X (150, 212). According to
reports to the OIE in 2006, 1.1% of 8 400 bovine
animals submitted for PPD tuberculin tests in
the Araucaria, Bio Bio and Los Lagos areas
were positive (83, 278). M. bovis strains have
been isolated from cattle condemned in
slaughterhouses (Metropolitan area, Santiago)

Bolivia
Bovine tuberculosis is prevalent in dairy cattle.
Surveillance activities are being conducted in
several regions of the country (Beni, La Paz,
Santa Cruz) by the application of intradermal
tuberculin tests using PPD and by culling
reactor animals (54). In the public health field,
there is a well organised tuberculosis
laboratory network. Cultures are performed on

Table III
Tuberculosis due to Mycobacterium bovis
Findings from two reference laboratories in Argentina
HIV (–) or not investigated
No. of cases of
Mycobacterium bovis (%)

HIV (+)
No. of cases of
Mycobacterium bovis (%)

Place

Years

Buenos Aires City

1981-1991
2000-2006

1 000 (0.95)
5 551 (0.22)

240 (0.83)
1 391 (0.58)

Santa Fe Province

1977-2000
2001-2006

3 946 (2.46)
5 901 (1.02)

ND*
ND*

HIV human immunodeficiency virus
ND not done
* no HIV(+) tuberculosis case diagnosed
Source: de Kantor & Ritacco (54), de Kantor & Ritacco (55), de Kantor et al. (56), Di Lonardo & Di Lenardo (67), Ritacco et al. (211),
Ritacco et al. (212)
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and submitted for molecular analysis (209). No
case of tuberculosis in humans due to M. bovis
has been reported in the last twelve years.

Colombia
Less than 0.01% of carcasses submitted for
veterinary inspection were condemned for
BTB; therefore, M. bovis infection is not
considered important among cattle (54, 83).
However, BTB infection in dairy cattle has
been detected by tuberculin tests in 1.2% of
herds investigated and M. bovis has been
isolated from bovine specimens. According to
periodic reports submitted to the OIE, BTB in
cattle continues to be detected in the
Cundinamarca and Antioquia provinces (2006‐
2007). Positive animals are removed from the
herd for slaughter (56). Since 1988, each
specimen submitted to the national reference
laboratory in Bogotá has been inoculated onto
two egg media, one containing glycerol and
the other pyruvate. M. bovis has been isolated
(56).

Cuba
The Control and Eradication Programme for
BTB started in the early 1960s. The
comparative tuberculin test with mammalian
and avian PPD was adopted and the positive
animals sent to slaughter. In the 1980s, most of
the positive animals necropsied did not have
macroscopic lesions and M. bovis was not
isolated by culture from the specimens
submitted (190). Surveillance activities are
being continued on a regular basis. In 2005, an
outbreak was notified to the OIE where one
animal was found to be positive out of
1 700 tested (278). To our knowledge, no
human case due to M. bovis has been reported
in the last 20 years.

Ecuador
Recently the presence of M. bovis has been
confirmed bacteriologically in samples form
tuberculin‐positive dairy cattle (201). M. bovis
has been isolated from two children with
extrapulmonary tuberculosis; ingestion of the
organism was the suspected route of infection.

Mexico
The National Campaign against BTB has
concentrated its actions on cattle. It is
especially active in the northern states of the
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country, from which nearly 1.2 million head
are exported to the United States each year.
The Animal Health authorities (Secretaría de
Agricultura, Ganadería, Desarrollo Rural, Pesca y
Alimentación: SAGARPA) reported in 2007 that
24 regions or states of the country achieved the
‘in eradication’ status, while the other
22 applied strict control measures (221).
Bovine tuberculosis infection persists in dairy
herds. It also affects beef cattle destined for
domestic consumption (161) from the central
and southern states. In a study performed in
2000 in Queretaro, 17% of 1 201 carcasses
submitted to veterinary inspection were
condemned due to tuberculosis lesions;
M. bovis was isolated from 79% of the samples
with most of the isolates from retropharyngeal
and mediastinal lymphatic nodes (160). In
2004, the USDA prohibited the importation of
Holstein and cross spayed heifers and steers
from Mexico because of the high incidence of
BTB in the Holstein breed (259). In 2006,
Mexico reported the detection of BTB in
94 herds to the OIE. A test and slaughter policy
was implemented (280).
As explained above, in public health
laboratories, bacteriological diagnosis of
tuberculosis is usually made by sputum smear
examination. Presence of BTB in humans had
not been confirmed until recently.
In San Diego, California, 7% of the tuberculosis
cases reported between 1994 and 2000 were
caused by M. bovis. Over 90% of these cases
were detected in the Mexican immigrant
community. About 25% of patients were
United States‐born Hispanic children and the
main site of disease was extra‐pulmonary
(138).
More recently, M. bovis infection was reported
in 35 patients in New York City between 2001
and 2004; 90% of the cases were diagnosed in
Mexican‐born immigrants and children.
Outbreaks were associated with the ingestion
of unpasteurised dairy products from Mexico.
No evidence of human‐to‐human transmission
was found (28). Results of a comprehensive
food investigation indicated that fresh cheese
brought to New York City from Mexico was a
likely source of infection (129). It must be
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emphasised that 30% of the 7 million litres of
milk annually produced in Mexico is not
pasteurised. This represents an unequivocal
risk of infection (287).

Panama
Panama attained the advanced stages of BTB
eradication in the early 1990s. However, in
1997, BTB was reported in Bocas del Toro, a
province located 500 km west of Panama City
that can only be reached by air or sea. In a
recent survey, 5% of 60 animals reacted to
tuberculin skin tests with PPD. M. bovis was
cultured from samples collected at necropsy
(25). There are no reports of cases of M. bovis
isolated from humans.

Peru
In 2002, in a survey conducted on
220 370 bovine animals in several regions of
the country the prevalence of tuberculin
reactors was 0.19% (82). However, percentages
are significantly higher in dairy herds in the
Lima (5.3%) and Arequipa (2.4%) regions (56).
In 2004, a total of 139 709 samples were
submitted for culture by the Public Health
Laboratory Network and 11.74% of these were
positive for M. tuberculosis. No M. bovis case in
humans has been confirmed. However, since
only glycerol containing egg media was used,
the presence of M. bovis as a source of human
disease can not be ruled out (56).

Uruguay
Regular BTB control activities implemented by
the dairy cooperative industry, were
introduced in the 1960s. Tuberculin reactors
detected were sent directly to special abattoirs.
As a result of these early activities, by 1989
only 0.4% of dairy herds had one or more
reactor animals. The official campaign of BTB
eradication was launched in 1996. In 2007, five
outbreaks were reported to the OIE; in all
cases,
the
animals
were
slaughtered
immediately and the carcasses destroyed. At
the national tuberculosis reference public
health laboratory, appropriate media were
used for isolation of M. bovis. However,
M. bovis has not been isolated from human
specimens in the last 20 years. There is a good
correlation here between the situation in
animal and public health (56).
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Venezuela
In 2003, a tuberculin testing survey was
performed in several regions of the country. Of
707 693 cattle tested, only 0.04% of the animals
were reactors in 5.2% of the herds investigated.
From 1999 to 2006; 8.55% of nearly
15 000 human samples submitted for culture
on egg media containing glycerol and
pyruvate were positive for the M. tuberculosis
complex. One isolate was identified as M. bovis
(Biomedicine Institute, Caracas) (56).

Human‐to‐human transmission of
Mycobacterium bovis
Recently, J.T. Evans et al. (75) reported six cases
of M. bovis in young people in the United
Kingdom. Only in the first patient diagnosed
(apparently the source case), was there
evidence
of
zoonotic
exposure
and
consumption of unpasteurised milk. Five of
the six cases presented smear‐positive
pulmonary disease at diagnosis and a history
of symptoms for several months before
commencing treatment. They could have had
multiple opportunities to spread the infection
by the respiratory route. These data confirm
that the transmission of M. bovis among
humans, from a smear‐positive tuberculosis
pulmonary patient to a susceptible but not
necessarily immunodepressed contact can take
place and the infection can evolve to
pulmonary disease, following a pattern similar
to that observed in the transmission of
M. tuberculosis.
Three nosocomial outbreaks of MDR‐TB
caused by M. bovis in patients infected with
HIV had been reported in Spain in the late
1990s (40). It was shown that AIDS patients
with a CD4 cell count below 50/l and exposed
to the index patient had an increased risk of
developing M. bovis disease (14, 215). Cases of
tuberculosis caused by the same genetically
identified M. bovis pattern were later detected
in immunocompetent persons. Recently in
Argentina two genetically identical M. bovis
isolates were recovered within a five year
interval from two tuberculosis pulmonary
patients, a father and daughter, who were not
infected by HIV (74).
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These reports confirm yet again that M. bovis
persists in humans and may be responsible for
morbidity and mortality (71). Several
comments arise from the above information, as
follows:
 the human‐to‐human transmission of
M. bovis exists and is possible in cases with
or without severe immunosuppression
 M. bovis strains can mutate to MDR and
these mutants can maintain the original
pathogenicity for humans
 eventually cattle and other animals may be
re‐infected with bovine tubercle bacilli
including MDR M. bovis strains.
Tuberculosis continues to be an important
disease both in humans and animals. It causes
substantial morbidity, mortality and economic
losses worldwide. There is significant variation
in terms of how different organisms of the
M. tuberculosis complex affect specific animals,
including humans. However, there are also
important intersections between animals and
humans with regard to tuberculosis and
perhaps the best example is the occurrence of
M. bovis disease in humans and domesticated
and wild animals.
M. bovis persists in humans, causing
pulmonary and extrapulmonary disease.
Unlike the transmission of M. bovis from cattle
to humans, the role of human‐to‐human
airborne transmission in the spread of M. bovis,
although controversial, does occur (246, 249).
The predominant view has been that human‐
to‐human transmission is a rare event and is
only likely to occur in populations that are
particularly
susceptible
to
tuberculosis
(e.g. HIV‐infected persons) (14). Prior reports
of clusters of cases with social and molecular
epidemiological links with patients with
pulmonary M. bovis have suggested that
human‐to‐human transmission does occur,
even in non‐immunosuppressed persons (75,
137, 138, 230, 249). The report by Evans et al. is
the best documented instance of multiple
events of likely human‐to‐human transmission
(246). This may be important in Africa where
HIV infection in humans is prevalent, M. bovis
infection in cattle is enzootic and pasteuris‐
ation of dairy products is not routinely
practised (287). In such a setting, disease
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introduced into the human population from
cattle could spread from human to human.
However, it should be noted that in Kruger
National
Park,
South
Africa,
where
tuberculosis is widespread in wild animals
M. bovis was not found to be an occupational
hazard nor was aerosol transmission
implicated as a mechanism for human
infection (269).

Future perspectives
Investigations are needed to elucidate the
relative importance of M. bovis on tuberculosis
incidence in humans, especially in developing
countries (71). Efforts should be concentrated
in countries where HIV infection is
widespread since these people are more
susceptible to M. bovis. Eradication of M. bovis
in cattle and pasteurisation of dairy products
are the cornerstones of prevention of human
disease (7). Standard public health measures
used to manage patients with contagious
M. tuberculosis should be applied to contagious
patients with M. bovis to stop person‐to‐person
spread. Finally, measures should be developed
to identify and control M. bovis infection in
wild animals as these animals may be
important
reservoirs
of
infection
for
domesticated food‐producing animals.
It is important to emphasise that pathogenic
tubercle bacilli have a wide host range; several
species of the genus Mycobacterium infect
humans as well as wild and domestic animals
(235). There is therefore a need for medical and
veterinary medical professionals to cooperate
in disease outbreaks (119, 270). This concept
has been promoted previously (168, 175, 250).
However, it should be emphasised that this is
of increasing importance in tuberculosis
control in the 21st century because of the
occurrence of drug resistant strains and reports
of immunosuppression of host responses
resulting in increased susceptibility to tubercle
bacilli.

Acknowledgements
The authors thank James H. Steele, Bruce
Kaplan, George Beran and Roseanne Miller for
reviewing the manuscript.

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

167

Tuberculosis: a re‐emerging disease in animals and humans

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

References
1.

American Thoracic Society and Centers for Disease Control and Prevention 2000. Targeted
tuberculin testing and treatment of latent tuberculosis infection. MMWR, 49 (RR-6), 1.

2.

American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases
Society 2003. Treatment of tuberculosis 2003. Am J Respir Crit Care Med, 167, 603.

3.

Allix C., Walravens K., Saegerman C., Godfroid J., Supply P. & Fauville-Dufaux M. 2006. Evaluation of
the epidemiological relevance of variable-number tandem-repeat genotyping of Mycobacterium
bovis and comparison of the method with IS6110 restriction fragment length polymorphism analysis
and spoligotyping. J Clin Microbiol, 44 (6), 1951-1962.

4.

Andersen P., Munk M.E., Pollock J.M. & Doherty T. 2000. Specific immune-based diagnosis of
tuberculosis. Lancet, 356, 1099.

5.

Aranaz A., Liebana E., Gomez-Mampaso E., Galan J.C., Cousins D., Ortega A., Blazquez J.,
Baquero F., Mateos A., Suarez G. & Dominguez L. 1999. Mycobacterium tuberculosis subsp. caprae
subsp. nov.: a taxonomic study of a new member of the Mycobacterium tuberculosis complex
isolated from goats in Spain. Int J System Bacteriol, 49, 1263-1273.

6.

Aranaz A, De Juan L., Montero N., Sánchez C., Galka M., Delso C., Alvarez J., Romero B., Bezos J.,
Vela A.I., Briones V., Mateos A. & Dominguez L. 2004. Bovine tuberculosis (Mycobacterium bovis) in
wildlife in Spain. J Clin Microbiol, 42 (6), 2602-2608.

7.

Ashford D.A., Voelker L. & Steele J.H. 2006. Bovine tuberculosis: environmental public health
preparedness considerations for the future. In Mycobacterium bovis infection in animals and
humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa,
305-315.

8.

Baker M.G., Lopez L.D., Cannon M.C., de Lisle G.W. & Collins D.M. 2006. Continuing Mycobacterium
bovis transmission from animals to humans in New Zealand. Epidemiol Infect, 134, 1068-1073.

9.

Barlow A.M., Mitchell K.A. & Visram K.H. 1999. Bovine tuberculosis in llama (Lama glama) in the UK.
Vet Rec, 145, 639-640.

10. Barrow P.A. & Gallagher J. 1981. Aspects of the epidemiology of bovine tuberculosis in badgers and
cattle. I. The prevalence of infection in two wild animal populations in south-west England. J Hyg
(Lond), 86 (3), 237-245.
11. Belli L.B. 1962. Bovine tuberculosis in a white-tailed deer (Odocoileus virginianus). Can Vet J, 3, 356358.
12. Bengis R.G., Kriek N.P.J., Keet D.F., Raath J.P., de Vos V. & Huchzermeyer H.F.A.K. 1996. An outbreak
of bovine tuberculosis in a free-living African buffalo (Syncerus caffer Sparrman) population in the
Kruger National Park: a preliminary report. Onderstepoort J Vet Res, 63 (1), 15-18.
13. Besser R.E., Pakiz B., Schulte J.M., Alvarado S., Zell E.R., Kenyon T.A. & Onorato I.M. 2001. Risk factors
for positive Mantoux tuberculin skin tests in children in San Diego, California: evidence for boosting
and possible foodborne transmission. Pediatrics, 108, 305-310.
14. Blazquez J., de Los Monteros L.E.E., Samper S., Martin C, Guerrero A., Cobo J., van Embden J.,
Baquero F. & Gomez-Mampaso E. 1997. Genetic characterization of multidrug-resistant
Mycobacterium bovis strains from a hospital outbreak involving human immunodeficiency viruspositive patients. J Clin Microbiol; 35, 1390-1393.
15. Blunden A.S. & Smith K.C. 1996. A pathological study of a mycobacterial infection in a cat caused
by a variant with cultural characteristics between Mycobacterium tuberculosis and M. bovis. Vet
Rec, 138 (4), 87-88.
16. Bolske G., Englund L., Wahlstrom H., Larsson B. & Robertson J.A. 2006. A tuberculosis outbreak in
farmed deer in Sweden and its economic consequences. In Mycobacterium bovis infection in
animals and humans (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa,
84-88.
17. Briones V., de Jean L., Sanchez C., Vela A.I., Galka M., Montero N., Goyache J., Aranaz A.,
Mateos A. & Dominguez L. 2000. Bovine tuberculosis and the endangered Iberian lynx. Emerg Infect
Dis, 6 (2), 189-191.
18. Brosch R., Gordon S.V., Marmiesse M., Brodin P., Buchrieser C., Eiglmeier K., Garnier T., Gutierrez C.,
Hewinson G., Kremer K., Parsons L.M., Pym A.S., Samper S., van Soolingen D. & Cole S.T. 2002. A new
evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci, 99, 36843689.

168

Vol. 45 (1), Vet Ital

www.izs.it/vet_italiana

© IZS A&M 2009

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

Tuberculosis: a re‐emerging disease in animals and humans

19. Bruning-Fann C.S., Schmitt S.M., Fitzgerald S.D, Fierke J.S., Friedrich P.D., Kaneene J.B., Clarke K.A.,
Butler K.L., Payeur J.B., Whipple D., Cooley T.M., Miller J.M. & Muzo D.P. 2001. Bovine tuberculosis in
free-ranging carnivores from Michigan. J Wildl Dis, 37, 58-64.
20. Buddle B.M., de Lisle G.W., Pfieffer A. & Aldwell F.E. 1995. Immunological responses and protection
against Mycobacterium bovis in calves vaccinated with a low dose of BCG. Vaccine, 13, 1123-1130.
21. Bush M., Montali R.J., Philips L. G. & Holobaugh P.A. 1990. Bovine tuberculosis in a Bactrian camel
herd: clinical, therapeutic, and pathologic findings. J Zoo Wildl Med, 21, 171-179.
22. Cabryn L.N. 1982. Incidence of disease and its potential role in the population dynamics of wolves
in Riding Mountain National Park, Manitoba. In Wolves of the world: perspectives on behavior,
ecology and conservation (F. Harrington & P.C. Paquet, eds). Noyes Publication, New Jersey, 106116.
23. Calle P.O., Thoen C.O. & Roskop M.L. 1989. Tuberculin skin test responses, mycobacteriologic
examinations of gastric lavage and serum enzyme-linked immunosorbent assays in orangutans
(Pongo pygmaeus). J Zoo Wildlife Med, 20 (3), 307-314.
24. Catanzaro A., Perry S., Clarridge J.E., Dunbar S., Goodnight-White S., LoBue P.A., Peter C.,
Pfyffer G.E., Sierra M.F., Weber R., Woods G., Mathews G., Jonas V., Smith K. & Della-Latta P. 2000.
The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a
multicenter prospective trial. J Am Med Assoc, 283, 639.
25. Cedeño I., de Obaldía R., Sanjur O., Bayard V., Ortega-Barría E. & Escobar C. 2005. Use of the
polymerase chain reaction for diagnosing bovine tuberculosis in Panama. Rev Sci Tech, 24, 10671075.
26. Centers for Disease Control and Prevention (CDC) 2005. Guidelines for the investigation of contacts
of persons with infectious tuberculosis. MMWR, 54 (RR-15), 1-47.
27. Centers for Disease Control and Prevention (CDC) 2005. Guidelines for using the Quantiferon®-TB
gold test for detecting Mycobacterium tuberculosis infection. MMWR, 54 (RR-15), 49-55.
28. Centers for Disease Control and Prevention (CDC) 2005. Human tuberculosis caused by
Mycobacterium bovis – New York City, 2001-2004. MMWR, 54, 605-608 (www.cdc.gov/mmwr/
preview/mmwrhtml/mm5424a4.htm accessed on 28 February 2009).
29. Centers for Disease Control and Prevention (CDC) 2007. Managing drug interactions in the
treatment of HIV-related tuberculosis. CDC, Atlanta (www.cdc.gov/tb/tb_hiv_Drugs/default.htm
accessed on 28 February 2009).
30. Centers for Disease Control and Prevention (CDC) 2007. Reported tuberculosis in the United States
2006. United States Department of Health and Human Services, CDC, Atlanta, 128 pp
(www.cdc.gov/tb/surv/surv2006/pdf/FullReport.pdf accessed on 27 February 2009).
31. Centers for Disease Control and Prevention (CDC) 2008. Trends in tuberculosis – United States, 2007.
MMWR, 57, 281-285.
32. Charcon O. & Bannantine J. 2006. DNA vaccines against tuberculosis. In Mycobacterium bovis
infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell
Publishing, Ames, Iowa, 285-304
33. Clancey J.K. 1977. The incidence of tuberculosis in lechwe (marsh antelope). Tubercle, 58, 151-156.
34. Cleaveland S., Miengeya T., Kazwala R.R., Michel A., Kaare M.T., Jones S.L., Eblate E., Shirma G.M. &
Packer C. 2005. Tuberculosis in Tanzanian wildlife. J Wildlife Dis, 41 (2), 446-453.
35. Clifton-Hadley R.S. 1996. Badgers, bovine tuberculosis and the age of reason. Br Vet J, 152 (3), 243246.
36. Clifton-Hadley R.S. & Wilesmith J.W. 1991. A prospective study of a badger population with endemic
tuberculosis (S.W. Martin, ed.). In Proc. Sixth International Symposium on Veterinary Epidemiology
and Economics (ISVEE), 12-16 August, Ottawa. ISVEE Office, Department of Population Medicine,
Ontario Veterinary College, University of Guelph, Guelph, Ontario, 434-436.
37. Clifton-Hadley R.S. & Wilesmith J.W. 1991. Tuberculosis in deer: a review. Vet Rec, 129, 5-12.
38. Clifton-Hadley R.S., Wilesmith J.W. & Stuart FA. 1991. Mycobacterium bovis in the European badger
(Meles meles): epidemiological findings in tuberculous badgers from a naturally infected
population. Epidemiol Infect, 111, 9-19.
39. Clifton-Hadley R.S., Wilesmith J.W., Richards M.S., Upton P. & Johnston S. 1995. The occurrence of
Mycobacterium bovis infection in and around an area subject to extensive badger (Meles meles)
control. Epidemiol Infect, 114, 179-193.

© IZS A&M 2009

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

169

Tuberculosis: a re‐emerging disease in animals and humans

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

40. Cobo J., Asensio A., Moreno A., Navas E.,Pintado V.,Oliva J., Gómez-Mampaso E. & Guerrero A.
2001. Risk factors for nosocomial transmission of multidrug-resistant tuberculosis due to
Mycobacterium bovis among HIV-infected patients. Int J Tuberc Lung, 5, 413-418.
41. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier, K., Gas S.,
Barry III C.E., Tekaia F., Badcock K., Basham D., Brown D., Chillingworth T., Connor R., Davies R.,
Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., K., Jagels K., Krogh A., McLean J.,
Moule S., Murphy L., Oliver K., Osborne J., Quail M.A., Rajandream M.A., Rogers J., Rutter S.,
Seeger K., Skelton J., Squares R., Squares S., Sulston J.E., Taylor K., Whitehead S. & Barrell B.G. 1998.
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.
Nature, 393, 537-544..
42. Coleman J.D., Cooke M.M., Jackson R. & Webster R. 1999. Temporal patterns in bovine tuberculosis
in a brushtail possum population contiguous with in infected cattle in the Ahaura Valley, Westland.
N Z Vet J, 47, 119-124.
43. Cooke M. 1998. Infectious diseases of possums in New Zealand. Surveillance, 25 (2), 10-12
44. Cosivi O., Grange J.M., Daborn C.J., Raviglione M.C., Fujikura T., Cousins D. Robinson R.A.,
Huchzermeyer H.F.A.K., de Kantor I & Meslin F.-X. 1998. Zoonotic tuberculosis due to Mycobacterium
bovis in developing countries. Emerg Infect Dis, 4, 59-70.
45. Corner L.A. 2006. The role of wild animal populations in the epidemiology of tuberculosis in domestic
animals: how to assess the risk. Vet Microbiol, 112, 303-312.
46. Costello E., O’Grady D., Flynn O., O’Brien R., Rogers M., Quigley F., Egan J., Griffin J. 1999. Study of
restriction fragment length polymorphism analysis and spoligotyping for epidemiological
investigation of Mycobacterium bovis infection. J Clin Microbiol, 37(10), 3217-3222.
47. Cousins D. 2006. Tuberculosis in fur seals and sea lions caused by Mycobacterium pinnipedii.
In Mycobacterium bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele &
M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 258-270.
48. Cousins D.V., Williams S.N, Reuter R., Forshaw D., Chadwicks B., Coughran D., Collins P. & Gales N.
1993. Tuberculosis in wild seals and characterization of the seal bacillus. Aust Vet J, 70 (3), 92-97
49. Cross M.L., Buddle B.M. & Aldwell F.E. 2007. The potential of oral vaccines for disease control. Vet J,
174, 472-480
50. Curry F.J., National Tuberculosis Center and California Department of Health Services 2008. Drug
resistant tuberculosis: a survival guide for clinicians, 2nd Ed. Francis J. Curry National Tuberculosis
Center, San Francisco, 266 pp (www.nationaltbcenter.edu/drtb/ accessed on 27 February 2009).
51. Dalovisio J.R., Stetter M. & Mikota-Wells S. 1992. Rhinoceros’ rhinorrhea: cause of an outbreak of
infection due to airborne Mycobacterium bovis in zookeepers. Clin Infect Dis, 14, 598-600.
52. Dankner W.M., Waecker N.J., Essey M.A., Moser K., Thompson M. & Davis C.E. 1993. Mycobacterium
bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of
a forgotten pathogen. Medicine (Baltimore), 72, 11-37.
53. Dean R.., Gunn-Moore D., Shaw S. & Harvey A. 2006. Bovine tuberculosis in cats. Vet Rec, 158 (12),
419-420.
54. de Kantor I.N. & Ritacco V. 1994. Bovine tuberculosis in Latin America and the Caribbean: current
status, control and eradication programs. Vet Microbiol, 40, 5-14.
55. de Kantor I.N. & Ritacco V. 2006. An update on bovine tuberculosis programmes in Latin American
and Caribbean countries. Vet Microbiol, 112, 111-118.
56. de Kantor I.N., Ambroggi M., Poggi S., Morcillo N., Da Silva Telles M.A., Osório Riveiro M., Garzón
Torres M.C., Llerena Polo C., Ribón W., García V., Kuffo D., Asencios L., Vásquez Campos L.M.,
Rivas C. & de Waard J.H. 2007. Human Mycobacterium bovis infection in ten Latin American
countries. Tuberculosis (Edinb), 88, 358-365.
57. de Kantor I.N. & Torres P.M. 2008. La tuberculosis bovina en la Argentina y en otros países de
América Latina. Su importancia zoonótica. In Temas de Zoonosis IV (R. Cacchione, R. Durlach &
O.P. Larghi, eds), Asociación Argentina de Zoonosis, Buenos Aires, 309-316.
58. Delahay R.J., De Leeuw A.N.S., Barlow A.M., Clifton-Hadley R.S. & Cheeseman C.L. 2002. The status
of Mycobacterium bovis infection in UK wild mammals: a review. Vet J, 164, 90-105.
59. de Lisle G.W. 1993. Mycobacterial infections in cats and dogs. Surveillance, 20 (4), 24-26.
60. de Lisle G.W., Collins D.M., Loveday A.S., Young W.A. & Julian A.F. 1990. A report of tuberculosis in
cats in New Zealand, and the examination of strains of Mycobacterium bovis by DNA restriction
endonuclease analysis. N Z Vet J, 38, 10-13.

170

Vol. 45 (1), Vet Ital

www.izs.it/vet_italiana

© IZS A&M 2009

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

Tuberculosis: a re‐emerging disease in animals and humans

61. de Lisle G.W., Crews K., de Zwart J., Jackson R., Knowles G.J.E., Paterson K.D., MacKenzie R.W.,
Waldrup K.A. & Wallace R. 1993. Mycobacterium bovis infections in wild ferrets. N Z Vet J, 41, 144146.
62. de Lisle G.W., Yates G.F., Collins D.M., MacKenzie R.W., Crews K.B. & Walker R. 1995. A study of
bovine tuberculosis in domestic animals and wildlife in the Mackenzie Basin and surrounding areas
using DNA fingerprinting. N Z Vet J, 43, 266-271.
63. de Lisle G.W., Mackintosh C.G. & Bengis R.G. 2001. Mycobacterium bovis in free-living and captive
wildlife, including farmed deer. Rev Sci Tech, 20, 86-111.
64. de Lisle G.W., Bengis R.G., Schmitt S.M. & O’Brien D.J. 2002. Tuberculosis in free-ranging wildlife:
detection, diagnosis and management. Rev Sci Tech, 21, 317-334.
65. De Vos V., Bengis R.G., Kriek N.P.J. Michel A., Keet D.F., Raath J.P. & Huchzermeyer H.F.K. 2001. The
epidemiology of tuberculosis in free-ranging African buffalo (Syncerus caffer) in the Kruger National
Park, South Africa. Onderstepoort J Vet Res, 68 (2), 119-130.
66. Di Lonardo M., Isola N.C., Ambroggi M., Rybko A. & Poggi S. 1995. Mycobacteria in HIV-infected
patients in Buenos Aires. Tuberc Lung Dis, 76, 185-189.
67. Di Lonardo M. & Di Lenardo M. 2003. Multidrug-resistant tuberculosis in HIV-negative patients,
Buenos Aires, Argentina. Emerg Infect Dis, 8, 965-969.
68. Dodd K. 1984. Tuberculosis in free-living deer. Vet Rec, 115, 592-593.
69. Dondo A., Ferroglio E., Goria M., Moda G., Ruocco L & Vignetta P. 2006. Economic significance of
bovine tuberculosis in Italy and effect of M. bovis infection in wild swine. In Mycobacterium bovis
infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell
Publishing, Inc., Ames, Iowa, 117-123.
70. Enarson D.A., Wang J.S. & Dirks J. 1989. The incidence of active tuberculosis in a large urban area.
Am J Epidemiol, 129, 1268-1276.
71. Enarson D.A. & Rieder H.L. 1995. The importance of Mycobacterium bovis to the tuberculosis
epidemic in humans. In Mycobacterium bovis infection in animals and humans, 1st Ed. (C.O. Thoen
& J.H. Steele, eds). Iowa State University Press, Ames, Iowa, xix-xxii.
72. Essey M.A., Payne R.L., Luschsinger D.W. & Himes E.M. 1981. Bovine tuberculosis surveys of axis deer
and feral swine on the Hawaiian island of Molokai. In Proc. 85th Annual Meeting of the United States
Animal Health Association, 11-16 October, St Louis, Missouri. Proc Ann Mtg USAHA, 87, 538-549.
73. Essey M.A., Stallknecht D.E., Himes E.M. & Harris S.K. 1983. Follow-up survey of feral swine for
Mycobacterium bovis infection on the Hawaiian island of Molokai. In Proc. 87th Annual Meeting of
the United States Animal Health Association, 16-21 October, Las Vegas, Nevada. Proc. Ann Mtg
USAHA, 87, 589-595.
74. Etchechoury I., Morcillo N., Sequeira M, Imperiale B., Echeverria G., Lopez M., Caimi K.,
Zumarraga M., Cataldi A. & Romano M.I. 2009. Detection and typing of Mycobacterium bovis from
patients with pulmonary tuberculosis in Argentina. Zoonoses Public Health (in press).
75. Evans J.T, Sonnenberg P., Grace Smith E., Banerjee A., Dale J., Innes J.A., Hunt D., Tweddell A.,
Wood A., Anderson C., Glyn Hewinson R., Smith N.H. & Hawkey P.M. 2007. Bovine tuberculosis:
multiple human-to-human transmission in the UK. Lancet, 14 (369), 1270-1276.
76. Ewer K., Deeks J., Alvarez L., Bryant G., Waller S., Anderson P., Monk P. & Lalvani A. 2003.
Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium
tuberculosis infection in a school tuberculosis outbreak. Lancet, 361, 1168.
77. Fanning A. & Edwards S. 1991. Mycobacterium bovis infection in human beings in contact with elk
(Cervus elaphus) in Alberta, Canada. Lancet, 338, 1253-1255.
78. Feldman W.H. 1934. Spontaneous tuberculous infection in dogs. J Amer Vet Med Assn, 85, 653-663.
79. Ferebee S.H. 1970. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc,
26, 28-106.
80. Fernández de Mera I.G., Pérez de la Lastra J.M., Ayoubi P., Naranjo V., Kocan K.M., Gortazar C. &
de la Fuente J. 2008. Differential expression of inflammatory and immune response genes in
mesenteric lymph nodes of Iberian red deer (Cervus elaphus hispanicus) naturally infected with
Mycobacterium bovis. Dev Comp Immunol, 32 (2), 85-91.
81. Flamand J.R., Greth A., Haagsma J. & Griffin J.F.T. 1994. An outbreak of tuberculosis in a captive
herd of Arabian oryx (Oryx leucoryx): diagnosis and monitoring. Vet Rec, 134 (5), 115-118.
82. Flores C.F., Delgado C.A., González Z.A. & Rivera H.G. 2005. Determinación de la presencia de
tuberculosis bovina en la provincia de Canta, Lima. Rev Investig Vet Perú, 16, 65-70.

© IZS A&M 2009

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

171

Tuberculosis: a re‐emerging disease in animals and humans

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

83. Food and Agriculture Organization (FAO). Global livestock production and health atlas. Animal
Production and Health Division, GLiPHA. 2008 (www.fao.org/ag/aga/glipha/index.jsp accessed
on26 February 2009).
84. Fowler M.E. 1978. Treating giraffes with isoniazid. In Proc. Symposium mycobacterial infections of zoo
animals (R.J. Montali, ed.). Smithsonian Institution Press, Washington, DC, 185-188.
85. Francis J. 1958. Tuberculosis in animals and man. Cassell and Co., Ltd, London, 357 pp.
86. Francis J. 1971. Susceptibility to tuberculosis and the route of infection. Aust Vet J, 47, 414.
87. Fremming B.D., Benson R.E., Young R.J. & Harris M.D. Jr 1957. Antituberculosis therapy in Macacca
mulatta monkeys. Amer Rev Tuberc Pulmonary Dis, 76, 225-231.
88. Friend M., Kroll E.T. & Graft H. 1963. Tuberculosis in a wild white-tailed deer. N Y Fish Game J, 10, 118123.
89. Frost P.A. 2006. Tuberculosis in nonhuman primates with an emphasis on Mycobacterium bovis.
In Mycobacterium bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele &
M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 271-284.
90. Gallagher J. 1980. The role of other animals in the epidemiology of TB of the badger. In Badgers,
cattle and tuberculosis: report to the Right Honourable Peter Walker, MBE, MP (O.M. Zuckerman,
ed.). Her Majesty’s Stationery Office, London, 203-217.
91. Gallagher J., Macadam I., Sayer J & Van Lavieren L.P. 1974. Pulmonary tuberculosis in free-living
lechwe antelope in Zambia. Trop Anim Hlth Prod, 4, 204-213.
92. Garnier T., Eiglmeier K., Camus J.C., Medina N., Mansoor H., Pryor M., Duthoy S., Grondin S.,
Lacroix C., Monsempe C., Simon S., Harris B., Atkin R., Doggett J., Mayes R., Keating L., Wheeler P.R.,
Parkhill J., Barrell B.G., Cole S.T., Gordon S.V. & Hewinson R.G. 2003. The complete genome
sequence of Mycobacterium bovis. Proc Natl Acad Sci,. 100, 7877-7882.
93. Gay G., Burbridge H.M., Bennett P., Fenwick S.G., Dupont C., Murray A. & Alley M.R. 2000. Pulmonary
Mycobacterium bovis in a dog. N Z Vet, 48 (3), 78-81
94. Gibson J.P., Rohovsky M.W. & Newberne J.W. 1971 Modification of the tuberculin response of rhesus
monkeys by isoniazid therapy. Lab Anim Sci, 21, 62-66.
95. Gill J.W. & Jackson R. 1993. Tuberculosis in a rabbit: a case revisited. N Z Vet J, 41, 147.
96. Gilsdorf M..J., Judge L. & Ebel E.D. 2006. Current challenges to and impacts on the U.S. national
bovine tuberculosis eradication program: Mycobacterium bovis outbreaks in alternate species and
surveillance performance. In Mycobacterium bovis infection in animals and humans, 2nd Ed.
(C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 211-225.
97. Goble M. 1994. Drug resistance. In Tuberculosis: current concepts and treatment (L. Friedman, ed.).
CRC Press, Boca Raton, 259.
98. Goodchild T. & Clifton-Hadley R. 2006. The fall and rise of bovine tuberculosis in Great Britain.
In Mycobacterium bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele &
M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 100-116.
99. Gortazar C., Vicente J., Samper S., Garrido J., Fernandez-De-Mera I.G., Gavin P., Juste R.A.,
Martin C., Acevedo P., De La Puente M. & Hofle U. 2005. Molecular characterization of
Mycobacterium tuberculosis complex isolates from wild ungulates in south-central Spain. Vet Res, 36,
43-52.
100. Griffin J.F.T., Chinn D.N. & Rodgers C.R. 2004. Diagnostic strategies and outcomes on three New
Zealand deer farms with severe outbreaks of bovine tuberculosis. Tuberculosis, 84, 293-302.
101. Griffin J.M., Williams D.H., Kelly G.E., Clegg T.A., O’Boyle I., Collins J.D. & Mave S.J. 2005. The impact
of badger removal on the control of bovine tuberculosis in cattle herds in Ireland. Prev Vet Med, 67,
237-266.
102. Gunn-Moore D.A., Jenkins P.A. & Lucke V.M. 1996. Feline tuberculosis: a literature review and
discussion of 19 cases caused by an unusual mycobacterial variant. Vet Rec, 138 (3), 53-58
103. Haagsma J. & Angus R.D. 1995. Tuberculin production. In Mycobacterium bovis infection in animals
and humans, 1st Ed. (C.O. Thoen & J.H. Steele, eds). Iowa State University Press, Ames, Iowa, 73-84.
104. Haberle A.J. 1970. Tuberculosis in an orangutan. J Zoo Anim Med, 1 (2), 10-15.
105. Hadwin S. 1942. Bovine tuberculosis in roe deer. J Am Vet Med Assoc, 100, 19-22.
106. Harris N.B. 2006. Molecular techniques: application in epidemiologic studies. In Mycobacterium
bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds).
Blackwell Publishing, Ames, Iowa, 54-62.

172

Vol. 45 (1), Vet Ital

www.izs.it/vet_italiana

© IZS A&M 2009

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

Tuberculosis: a re‐emerging disease in animals and humans

107. Havlir D.V. & Barnes P.F. 1999. Tuberculosis in patients with human immunodeficiency virus infection.
N Engl J Med, 340,367.
108. Hein W.R. & Tomasovic A.A. 1981. An abattoir survey of tuberculosis in feral buffaloes. Aust Vet J, 57,
543-547.
109. Helman R.G., Rusell W.C., Jenny A. Miller J. & Payer J. 1998. Diagnosis of tuberculosis in two snow
leopards using polymerase chain reaction. J Vet Diagn Invest, 10, 89-92.
110. Hewinson R.G., Vordermeier H.M., Smith N.H. & Gordon S.V. 2006. Recent advances in our
knowledge of Mycobacterium bovis: a feeling for the organism. Vet Microbiol, 112,127-139.
111. Himes E.M., Luchsinger D.L., Jarnagin J.L, Thoen C.O., Hood H.H. & Ferrin D.A. 1980. Tuberculosis in
fennec foxes. J Amer Vet Med Assn, 177, 825-826.
112. Hines N., Payeur J.B. & Hoffman L.J. 2006. Comparison of the recovery of Mycobacterium bovis
isolates using the BACTEC MGIT 960 system, BACTEC 460 system, and Middlebrook 7H10 and 7H11
solid media. J Vet Diagn Invest, 18, 243-250.
113. Hlavsa M., Moonan P.K., Cowan L.S., Navin T.R., Kammerer J.S., Morlock G.P., Crawford J.T. &
LoBue P.A. Human tuberculosis caused by Mycobacterium bovis in the United States, 1995-2005.
Clin Infect Dis, 47 (2), 168-175.
114. Hope J.C. & Villarreal-Ramos B. 2008. Bovine TB and the development of new vaccines. Comp
Immunol Microbiol Infect Dis. 31, 77-100.
115. Institute of Medicine 2000. Ending neglect: the elimination of tuberculosis in the United States.
National Academy of Sciences, Washington, DC, 27-29.
116. Issac J., Whitehead J., Adams J.W., Barton M.D. & Coloe P. 1983. An outbreak of Mycobacterium
bovis infection in cats in an animal house. Aust Vet J. 60, 243-245.
117. Jones B.E., Young S.M. & Antoniskis D. 1993. Relationship of the manifestations of tuberculosis to CD4
cell counts in patients with human immunodeficiency virus. Am Rev Respir Dis, 148, 1292.
118. Jorgenson J.B., Husum P. & Sorensen C.I. 1988. Bovine tuberculosis in a deer farm. Dansk Vettidsskr,
71, 806-808.
119. Kahn L.H., Kaplan B. & Steele J.H. 2007. Confronting zoonoses through closer collaboration between
medicine and veterinary medicine (as ‘one medicine’). Vet Ital, 43 (1), 5-19.
120. Kaneene J.B., Bruning-Fann C., Dunn J., Mullaney T., Berry D., Massey J., Thoen C.O., Halstead S. &
Schwartz K. 2002. Epidemiologic investigation of Mycobacterium bovis in a population of cats. J Am
Vet Med Assoc, 63, 1507-1511.
121. Kaneene J.B., Vander Klok M., Bruning-Fann C.S. & Miller R. 2002. The prevalence of Mycobacterium
bovis in privately-owned cervid ranches in Michigan. J Am Vet Med Assoc, 220 (5), 656-659.
122. Kaneene J.B. & Thoen C.O. 2004. Tuberculosis. J Am Vet Med Assoc, 224 (5), 685-691.
123. Kaneene J. B. & Pfieffer D. 2006. Epidemiology of Mycobacterium bovis. In Mycobacterium bovis
infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell
Publishing, Ames, Iowa, 44-58.
124. Karlson A.G. 1962. Nonspecific or cross-sensitivity reactions to tuberculin in cattle. In Advances in
veterinary science, 7th Ed. (C.A. Brandly & E.L. Jungherr, eds). Academic Press, New York, 147-181.
125. Keating L.A., Wheeler P.R., Mansoor H., Inwald J.K., Dale J., Hewinson R.G. & Gordon S.V. 2005. The
pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an
inactive pyruvate kinase: implications for in vivo growth. Mol Microbiol, 56, 163-174.
126. Keet D.F., Kriek N.P.J., Penrith M.L., Michel A. & Huchzermeyer H. 1996. Tuberculosis in buffaloes
(Syncerus caffer) in the Kruger National Park: spread of the disease to other species. Onderstepoort
J Vet Res, 63 (3), 239-244.
127. Keet D.F., Kriek N.P.J., Bengis R.G., Grobler D.G. & Michel A. 2000. The rise and fall of tuberculosis in a
free-ranging chacma baboon troop in the Kruger National Park. Onderstepoort J Vet Res, 67 (2),
115-22.
128. Keet D.F., Kriek N.P.J., Bengis R.G. & Michel A. 2001. Tuberculosis in kudus (Tragelaphus strepsiceros)
in the Kruger National Park. Onderstepoort J Vet Res, 68 (3), 225-230.
129. Kinde H., Mikolon A., Rodriguez-Lainz A., Adams C., Walker R.L., Cernek-Hoskins S., Treviso S.,
Ginsberg M., Rast R., Harris B., Payeur J.B., Waterman S. & Ardans A. 2007. Recovery of Salmonella,
Listeria monocytogenes, and Mycobacterium bovis from cheese entering the United States through
a noncommercial land port of entry. J Food Prot, 70, 47-52.
130. Koch R. 1882. Die aetiologie der Tuberculose. Berlin Klin Wchschr, 19, 221-230.

© IZS A&M 2009

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

173

Tuberculosis: a re‐emerging disease in animals and humans

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

131. Koller-Jones M.A., Turcotte C., Lutze-Wallace C. & Surujballi O. 2006. Effect of bovine tuberculosis in
wildlife on a national eradication program-Canada. In Mycobacterium bovis infection in animals
and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa,
226-237.
132. Kopanoff D.E., Snider D.E. & Caras G.J. 1978. Isoniazid-related hepatotoxicity: a US Public Health
Service cooperative surveillance study. Am Rev Respir Dis, 117, 991.
133. Kriek N. 2006. Bovine tuberculosis program in South Africa: the impact of M. bovis-infected wild
species. In Mycobacterium bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele
& M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 238-243.
134. Leung A.N., Muller N.L., Pineda P.R. & FitzGerald J.M. 1992. Primary tuberculosis in childhood:
radiographic manifestations. Radiology, 182, 87.
135. Levine P.P. 1934. A report on tuberculosis in wild deer (Odocoileus virginianus). Cornell Vet, 24, 264266.
136. Little T.W.A., Swan C., Thompson H.V. & Wilesmith J.W. 1982. Bovine tuberculosis in domestic and
wild mammals in an area of Dorset. II. The badger population, its ecology and tuberculosis status.
J Hyg Camb, 89, 211-224.
137. LoBue P. 2006. Public health significance of M. bovis. In Mycobacterium bovis infection in animals
and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing. Ames, Iowa,
6-12.
138. LoBue P.A., Betacourt W., Peter C. & Moser K.S. 2003. Epidemiology of Mycobacterium bovis disease
in San Diego County, 1994-2000. Int J Tuberc Lung Dis, 7, 180-185.
139. LoBue P.A. & Moser KS. 2003. Use of isoniazid for latent tuberculosis infection in a public health clinic.
Am J Respir Crit Care Med, 168, 443.
140. LoBue P.A & Moser K.S. 2005. Isoniazid- and rifampin-resistant tuberculosis in San Diego County,
California, United States, 1993-2002. Int J Tuberc Lung Dis, 9, 501.
141. LoBue P.A. & Moser K.S. 2005. Treatment of Mycobacterium bovis infected tuberculosis patients, San
Diego, California, United States, 1994-2003. Int J Tuberculosis Lung Dis, 9, 333-338.
142. Lomme J.R., Thoen C.O., Himes E.M., Vincent J.W. & King R.E. 1976. Mycobacterium tuberculosis:
infection in two East African oryxes. J Am Vet Med Assoc, 169, 912.
143. Lugton I.W., Johnstone A.C. & Morris R.A. 1995. Mycobacterium bovis infection in New Zealand
hedgehogs (Erinaceous europaeus). N Z Vet J, 43, 342-345.
144. Lugton I., Wobeser G., Morris R., Caley P. 1995. A study of Mycobacterium bovis infection in wild
ferrets. In Tuberculosis in wildlife and domestic animals, Otago Conference Series, No. 3. University of
Otago Press, Dunedin, 239-242.
145. Lumerj J.T., Hajer R., Dik K.J., Dorrestein G.M. & Engel H.W.B. 1987. Diagnosis of pulmonary
Mycobacterium bovis infection in a tiger. Vet Rec, 120, 302-304.
146. Lyashchenko K.P., Greenwald R., Esfandiari J., Chambers M.A., Vicente J., Gortazar C., Santos N.,
Correia-Neves M., Buddle B.M., Jackson R., O’Brien D.J., Schmitt S., Palmer M.V., Delahay R.J. &
Waters W.R. 2008. Animal-side serologic assay for rapid detection of Mycobacterium bovis infection
in multiple species of free-ranging wildlife. Vet Microbiol, 132, 283-292.
147. Lyashchenko K.P., Greenwald R., Esfandiari J., Greenwald D., Nacy C.A., Gibson S., Didier P.J.,
Washington M., Szczerba P., Motzel S., Handt L., Pollock J.M., McNair J., Andersen P., Langermans
J.A.M., Verreck F., Ervin S., Ervin F. & McCombs C. 2007. Prima TB STAT-PAK assay, a novel, rapid
lateral-flow test for tuberculosis in nonhuman primates. Clin Vaccine Immunol, 14 (9), 1158-1164.
148. McAdams H.P., Erasmus J. & Winter A. 1995. Radiologic manifestations of pulmonary tuberculosis.
Radiol Clin North Am, 33, 655.
149. McInerney J.P., Small K.J. & Caley P. 1995. Prevalence of Mycobacterium bovis infection in feral pigs
in the Northern Territory. Aust Vet J, 72 (12), 448-451.
150. Mancilla M.E., Martínez A.H., Palavecino C.B., Rehren G.S., Lucero P.L., León G.R. & Zárraga A.-M.O.
2006. Variantes genéticas de Mycobacterium tuberculosis aisladas de pacientes de la Xa Región
de Chile [Genetic variants of Mycobacterium tuberculosis isolated frm patients of the Xth Region of
Chile]. Rev Chil Infect, 23, 220-225.
151. Martinez L.R., Harris B., Black W.C. IV, Meyer R.M., Brennan P.J., Varalakshmi D. & Jones R.L. 2008.
Genotyping North American animal Mycobacterium bovis isolates using multilocus variable number
tandem repeat analysis. J Vet Diag Invest, 20 (6), 707-715.

174

Vol. 45 (1), Vet Ital

www.izs.it/vet_italiana

© IZS A&M 2009

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

Tuberculosis: a re‐emerging disease in animals and humans

152. Mathews F., Macdonald D.W., Taylor G.M., Gelling M., Norman R.A, Honess P.E., Foster R.,
Gower C.M., Varley S., Harris A., Palmer S., Hewinson G. & Webster J.P. 2006. Bovine tuberculosis
(Mycobacterium bovis) in British farmland wildlife: the importance to agriculture. Proc Biol Soc, 273,
357-365.
153. Maue A.C., Waters W.R., Palmer M.V., Nonnecke B.J., Minion F.C., Brown W.C., Norimine J.,
Foote M.R., Scherer C.F.C. & Estes D.M. 2007. An ESAT-6:CFP10 DNA vaccine administered in
conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent
M. bovis. Vaccine, 25, 4735-4746.
154. Michalak K.C., Austin S., Diesel J., Bacon J.M., Zimmerman P. & Maslov J.N. 1998. Mycobacterium
tuberculosis infection as a zoonotic disease: transmission between humans and elephants. Emerg
Infect Dis, 4, 283-287.
155. Michel A.L. 2002. Implications of tuberculosis in African wildlife and livestock. Ann N Y Acad Sci, 969,
251-255.
156. Michel A.L & Huchzermeyer H.F.A.K. 1998. The zoonotic importance of Mycobacterium tuberculosis:
transmission from human to monkey. J S Afr Vet Assoc, 69, 64-65.
157. Michel A.L., Bengis R.G., Keet D.F., Hofmeyr M., de Klerk L.M., Cross P.C., Jolles A.E., Cooper D.,
Whyte I.J., Buss P. & Godfroid J. 2006. Wildlife tuberculosis in South African conservation areas:
implications and challenges. Vet Microbiobiol, 112 (2-4), 91-100.
158. Michigan Government 2008. Summary of Michigan wildlife bovine tuberculosis surveillance.
Michigan Department of Natural Resources Wildlife Disease Lab, 3 July. Document IC 2390-6
(11/04/1999), 1 p (www.michigan.gov/documents/emergingdiseases/WildlifeTBSurveillanceSumm
ary_211947_7.pdf, accessed on 28 February 2009).
159. Mikota S.K, Peddie L., Peddie J., Isaza, R., Dunker F., West G., Lindsay W., Larsen S., Salman M.D.,
Chatterjee D., Payeur J., Whipple D., Thoen C.O., Davis D.S., Sedgwick C., Montali R.J., Ziccardi M. &
Maslow J. 2001. Epidemiology and diagnosis of Mycobacterium tuberculosis in captive Asian
elephants (Elephas maximus). J Zoo Wildl Med, 32, 1-16.
160. Milian-Suazo F., Salman M.D., Ramirez C., Payeur J.B., Rhyan J.C. & Santillan M. 2000. Identification
of tuberculosis in cattle slaughtered in Mexico. Am J Vet Res, 61, 86-89.
161. Milian Suazo F., Banda-Ruiz V., Ramírez Casillas C. & Arriaga-Diaz C. 2002. Genotyping of
Mycobacterium bovis by geographic location within Mexico. Prev Vet Med, 55, 255-264.
162. Miller J., Jenny A., Rhyan J., Saari D. & Suarez D. 1997. Detection of Mycobacterium bovis in
formalin-fixed, paraffin-embedded tissues of cattle and elk by PCR amplification of an IS6110
sequence specific for Mycobacterium tuberculosis complex organisms. J Vet Diagn Invest, 9, 244249.
163. Miller R., Kaneene J.B., Fitzgerald S.D. & Schmitt S.M. 2003. Evaluation of the influence of
supplemental feeding of white-tailed deer (Odocoileus virginianus) on the prevalence of bovine
tuberculosis in the Michigan wild deer population. J Wildlife Dis, 39 (1), 84-95.
164. Miller R. & Kaneene J.B. 2006. Evaluation of historical factors influencing the occurrence and
distribution of Mycobacterium bovis infection among wildlife in Michigan. Am J Vet Med, 67 (4),
604-615.
165. Miller R., Kaneene J.B, Schmitt S.M., Lusch D.P. & Fitzgerald S.D. 2007. Spatial analysis of
Mycobacterium bovis infection in white-tailed deer (Odocoileus virginianus) in Michigan, USA. Prev
Vet Med, 82, 111-122.
166. Ministério da Agricultura, Pecuária e Abastecimento, Brazil 2008. Programa Nacional de controle e
erradicação de brucelose e da tuberculose animal (PNCEBT). Ministério da Agricultura, Pecuária e
Abastecimento, Brasilia (www.agricultura.gov.br accessed on 20 February 2009).
167. Mirsky M.L., Morton D., Piehl J.W. & Gelberg H. 1992. Mycobacterium bovis in a captive herd of Sika
deer. J Am Vet Med Assoc, 200, 1540-1542.
168. Moda G. & Valpreda M. 1994. Bovine tuberculosis eradication: need of collaboration between
physicians and veterinarians. Alpe Adria Microbiol J, 3, 296-297.
169. Monies B., Jahans K. & de la Rua R. 2006. Bovine tuberculosis in cats. Vet Rec, 158, 245-246.
170. Mori T., Sakatani M., Yamagishi F., Takashima T., Kawabe Y., Nagao K., Shigeto E., Harada N., Mitarai
S., Okada M., Suzuki K., Inoue Y., Tsuyuguchi K., Sasaki Y., Mazurek G.H. & Tsuyuguchi I. 2004. Specific
detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J
Respir Crit Care Med, 170, 59.
171. Morris P.J., Thoen C.O. & Legendre A.M. 1996. Pulmonary tuberculosis in an African lion (Panthera
leo). J Zoo Wildl Med, 27 (3), 392-396.

© IZS A&M 2009

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

175

Tuberculosis: a re‐emerging disease in animals and humans

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

172. Morris R.S., Pfeiffer D.U. & Jackson R. 1994. The epidemiology of Mycobacterium bovis infections. Vet
Microbiol, 40, 153-177.
173. Morris R.S. & Pfeiffer D.U. 1995. Directions and issues in bovine tuberculosis epidemiology and control
in New Zealand. N Z Vet J, 43, 256-265.
174. Murihead R. H., Gallagher J. & Burn K.J. 1974. Tuberculosis in wild badgers in Gloucester:
epidemiology. Vet Rec, 95, 552-555.
175. Myers J.A. & Steele J.H. 1969. Bovine tuberculosis control in man and animals. Warren H. Green, Inc.,
St Louis, Missouri, 403 pp.
176. Naranjo V., Gortazar C., Vicente J. & de la Fuente J. 2008. Evidence of the role of European wild
boar as a reservoir of Mycobacterium tuberculosis complex. Vet Microbiol, 127, 1-9.
177. Nishi J.S., Shury T. & Elkin B.T. 2006. Wildlife reservoirs for bovine tuberculosis (Mycobacterium bovis) in
Canada: strategies for management and research. Vet Microbiol, 112, 325-338.
178. Nolan C.M., Goldberg S.V. & Buskin S.E. 1999. Hepatotoxicity associated with isoniazid preventive
therapy: a seven year survey from a public health clinic. J Amer Med Assoc, 281, 1014.
179. Nugent G. & Lugton I. 1995. Prevalence of bovine tuberculosis in wild deer in the Hauhungaroa
range, North Island, New Zealand. In Tuberculosis in wildlife and domestic animals, Otago
Conference Series No. 3. University of Otago Press, Dunedin, 273-275.
180. O’Brien D.J., Fitzgerald, S.D., Lyon T.J., Butler K.I., Fierke J.S., Clarke K.R., Schmitt S.M. Cooley T.M. &
Derry D.E. 2001. Tuberculous lesions in free-ranging white-tailed deer in Michigan. J Wildlife Dis, 37,
608-613.
181. O’Brien D.J, Schmitt S.M., Fitzgerald S.D., Berry D.E & Hickling G.J. 2006. Managing the wildlife
reservoir of Mycobacterium bovis: the Michigan, USA, experience. Vet Microbiol, 112, 313-323.
182. Oh P., Granich R., Scott .J, Sun B., Joseph M., Stringfield C., Thisdell S., Staley J., Workman-Malcolm
D., Borenstein L., Lehnkering E., Ryan P., Soukup J., Nitta A. & Flood J. 2002. Human exposure
following Mycobacterium tuberculosis infection in multiple animal species in a metropolitan zoo.
Emerg Infect Dis, 8, 1290-1293.
183. Olsen I., Barletta R.G & Thoen C.O. 2010. Mycobacterium. In Pathogenesis of bacterial infections in
animals (C.L. Gyles, J.F. Prescott, J.G. Songer & C.O. Thoen, eds). John Wiley & Sons, Ames, Iowa (in
press).
184. O’Reilly L.M. 1995. Tuberculin skin test sensitivity and specificity. In Mycobacterium bovis infection in
animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing,
Ames, Iowa, 177-183.
185. O’Reilly L.M. & Costello E. 1988. Bovine tuberculosis with special reference to the epidemiological
significance of pulmonary lesions. Ir Vet News, 10, 11-21.
186. O’Reilly L.M. & Daborn C.J. 1995. The epidemiology of Mycobacterium bovis infections in animals
and man: a review. Tubercule Lung Dis, 76 (S1), 1-46.
187. Palmer M.V., Waters W.R., Thacker T.C., Greenwald R., Esfandiari J. & Lyashchenko K.P. 2006. Effects
of different tuberculin skin-testing regiments on gamma interferon and antibody responses in cattle
experimentally infected with Mycobacterium bovis. Clin Vaccine Immunol, 13 (3), 387-394.
188. Palmer M.V., Whipple D.L., Payeur J.B., Alt D.P., Esch K.J., Bruning-Fann C.S. & Kaneene J.B. 2000.
Naturally occurring tuberculosis in white-tailed deer. J Am Vet Med Assoc, 216 (2), 1921-1924.
189. Pan American Health Organization/World Health Organization (PAHO/WHO). 1992. Action plan for
the eradication of bovine tuberculosis in the Americas, Phase 1. HPV/TUB/113/92. PAHO/WHO,
Washington DC. Prev Vet Med, 55, 255-264.
190. Pan American Health Organization/World Health Organization (PAHO/WHO) 2008. Manual for the
Bacteriological diagnosis of tuberculosis: standards and technical guidelines, Part 2, Cultures. PAHO,
Washington, DC (www.paho.org/English/HCP/HCT/TUB/tuberculosis.htm accessed on 27 February
2009).
191. Parra A., Fernandez-Llario P., Tato A., Larrasa J., Garcia A., Alonso J.M., Hermoso de Mendoza M. &
Hermoso de Mendoza J. 2003. Epidemiology of Mycobacterium bovis infections of pigs and wild
boars using a molecular approach. Vet Microbiol, 97,123-133.
192. Parra A., Larrasa J., Garcia A., Alonso J.M. & Hermoso de Mendoza J. 2005. Molecular epidemiology
of bovine tuberculosis in wild animals in Spain: a first approach to risk factor analysis. Vet Microbiol,
110, 293-300.
193. Pate M., Svara T., Gombac M., Paller T., Zolnir-Dovc M., Emersic I., Prodinger W.M., Bartos M.,
Zdocv I., Krt B., Pavlik I., Cvetnić Z., Pogacnik M. & Ocepek M. 2006. Outbreak of tuberculosis

176

Vol. 45 (1), Vet Ital

www.izs.it/vet_italiana

© IZS A&M 2009

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

Tuberculosis: a re‐emerging disease in animals and humans

caused by Mycobacterium caprae in a zoological garden. J Vet Med B Infect Dis Vet Public Health,
53 (8), 387-392.
194. Pattyn S.R., Boveroulle M.T., Mortelmans J & Vercruysse J. 1967. Mycobacteria in mammals and birds
of the zoo of Antwerp. Acta Zool Pathol Antwerp, 43, 125-128.
195. Pavlik I. 2006. Bovine tuberculosis in Russia and the Former States of the Soviet Union.
In Mycobacterium bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele &
M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 173-188.
196. Pavlik I. 2006. Control and eradication of bovine tuberculosis in Central Europe In Mycobacterium
bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds).
Blackwell Publishing, Ames, Iowa, 136-148.
197. Pavlik I., Machackova M., Yayo Ayele W., Lamka J., Parmova I., Melicharedk M., Hanzlikova B.,
Karmendy B., Nagy G., Cvetnić Z., Ocepek M. & Lipiec M. 2002. Incidence of bovine tuberculosis in
wild and domestic animals other cattle in six central European countries during 1990-1999. Vet MedCzeck, 47 (5), 122-131.
198. Payeur J.B., Church S., Mosher L., Robinson-Dunn B., Schmitt S.M. & Whipple D. 2002. Bovine
tuberculosis in Michigan wildlife. Ann N Y Acad Sci, 969, 259-261.
199. Pollock J.M. & Andersen P. 1997. Predominant recognition of the ESAT-6 protein in the first phase of
interferon with Mycobacterium bovis in cattle. Infect Immun, 65 (7), 2587-2592.
200. Potkay S., Ganaway J.R., Rogers N. & Kirnard R. 1966. Epizootic of measles in a colony of rhesus
monkeys (Macaca mulatta). Am J Vet Res, 27, 331-334.
201. Proaño-Perez F., Rigouts L., Brandt J., Dorny P., Ron J., Chavez M.A., Rodriguez R., Fissete K., Van
Aerde A., Portaels F. & Benítez-Ortiz W. 2006. Preliminary observations on Mycobacterium spp. in
dairy cattle in Ecuador. Am J Trop Med Hyg, 75, 318-323.
202. Quigley F.C., Costello E., Flynn O., Gogarty A., McGuirk J., Murphy A. & Egan J. 1997. Isolation of
mycobacteria from lymph node lesions in deer. Vet Rec, 141 (20), 516-518.
203. Quinn J.F. & Towar D. 1963. Tuberculosis problems in a deer park in Michigan. In Proc. 100th Annual
Meeting of the American Veterinary Medical Association. American Veterinary Medical
Association, Schaumburg, Illinois, 262-264.
204. Quinn P.J. & Collins J.D. 2006. The effect of wildlife reservoirs on Mycobacterium bovis in programs
for the eradication of tuberculosis in cattle in Ireland. In Mycobacterium bovis infection in animals
and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa,
124-135.
205. Ragg J.R., Moller H. & Waldrup K.A. 1995. The prevalence of bovine tuberculosis (Mycobacterium
bovis) infections in feral populations of cats (Felis catus), ferrets (Mustela furo) and stoats (Mustela
erminea) in Otago and Southland, New Zealand. N Z Vet J, 43, 333-337.
206. Ragg J.R., Waldrup K.A. & Moller H. 1995. The distribution of gross lesions of tuberculosis caused by
Mycobacterium bovis in feral ferrets (Mustela furo) from Otago, New Zealand. N Z Vet J, 43, 338-341.
207. Ragg J.R., Mackintosh C.G. & Moller H. 2000. The scavenging behaviour of ferrets (Mustela furo),
feral cats (Felis domesticus), possums (Trichosurus vulpecula), hedgehogs (Erinaceus europaeus)
and harrier hawks (Circus approximans) on pastoral farmland in New Zealand: implications for
bovine tuberculosis transmission. N Z Vet J, 48,166-175.
208. Ramos A., Noblejas A., Martín T., Varela A., Daza R. & Samper S. 2004. Prolonged survival of an HIVinfected patient with multidrug-resistant Mycobacterium bovis infection treated with surgical
resection. Clin Infect Dis, 39, e53-e55.
209. Retamal P., Martinez M.A. & Abalos P. 2003. Secuencias de inserción IS6110 e IS1081 en cepas de
Mycobacterium bovis provenientes de bovinos beneficiados en la Región Metropolitana. Rev Chil
Infect, 20, 166-170.
210. Rhyan J., Aune K., Clarke R., Meyer R., Siroky C. & Stackhouse L. 1995. Discovery of bovine
tuberculosis in free-ranging mule deer and results of continued wildlife surveillance in the area.
In Proc. Veterinary epidemiology and economics symposium, 31 May-2 June, Centers for
Epidemiology and Animal Health, APHIS, USDA, Fort Collins, Colorado, 1B2-1B4.
211. Ritacco V., Sequeira M.D. & de Kantor I.N. 2006. Human tuberculosis caused by Mycobacterium
bovis in Latin America and the Carribbean. In Mycobacterium bovis infection in animals and
humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 1317.

© IZS A&M 2009

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

177

Tuberculosis: a re‐emerging disease in animals and humans

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

212. Ritacco V., Torres P.M., Sequeira M.D., Reniero A. & de Kantor I.N. 2006. Bovine tuberculosis in Latin
America and the Caribbean. In Mycobacterium bovis infection in animals and humans, 2nd Ed.
(C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 149-160.
213. Russell D.G. 2007. Who puts the tubercle in tuberculosis? Nature Rev Microbiol, 5, 39-47.
214. Ryan T.J., Livingstone P.G., Bailey J.B., Carter C.E., Crews K.B., Timbs D.V. & Thrusfield M.V. 1998.
Tuberculosis control in livestock in New Zealand. The current situation and future directions. In Proc.
Society for Veterinary Preventive Medicine (E.A. Goodall, ed.), 25-27 March, Ennis, Co. Clare, 1-14.
215. Samper S., Martin C., Pinedo A., Rivero A., Blázquez J., Baquero F., Van Soolingen D. & Van
Embden J. 1997. Transmission between HIV-infected patients of multidrug-resistant tuberculosis
caused by Mycobacterium bovis. AIDS, 11, 1237-1242.
216. Sapolsky R.M. & Else J.G. 1987. Bovine tuberculosis in a wild baboon population: epidemiological
aspects. J Med Primatol, 16 (4), 229-235.
217. Sawa T.R., Thoen C.O. & Nagao W.T. 1974. Mycobacterium bovis infection in wild axis deer in Hawaii.
J Am Vet Med Assoc. 164(11), 998-999.
218. Schliesser T.A. 1978. Prevalence of tuberculosis and mycobacterial diseases in some European zoos
(R.J. Montali, ed.). Smithsonian Institution Press, Washington, DC, 29-32.
219. Schmitt S.M., Fitzgerald S.D., Cooley T.M., Bruning-Fann C.S., Sullivan L., Berry D., Carlson T.,
Minnis R.B., Payeur J.B. & Sikarskie J. 1997. Bovine tuberculosis in free-ranging white-tailed deer in
from Michigan. J Wildlife Dis, 33 (3), 749-758.
220. Schmitt S.M., O’Brien D.J., Bruning-Fann C.S. & Fitzgerald S.D. 2002. Bovine tuberculosis in Michigan
wildlife and livestock. Ann NY Acad Sci, 969, 262-268.
221. Secretaría Agricultura Ganadería Desarrollo Rural, Pesca y Alimentación (SAGARPA) 2008.
Campaña nacional contra la tuberculosis bovina y brucelosis (www.sagarpa.gob.mx/dlg/chiapas/
ganaderia/camapa%F1atuberculosisBovina.htm accessed on 18 February 2009).
222. Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., Walker A.T. &
Friedland G.H. 1989. A prospective study of the risk of tuberculosis among intravenous drug users
with human immunodeficiency virus infection. N Engl J Med, 230, 545, 1989.
223. Serraino A., Marchetti G., Sanguinetti V., Rossi M.C., Zanoni R.G., Catozzi L., Bandera A., Dini W.,
Mignone W., Franzetti F. & Gori A. 1999. Monitoring of transmission of tuberculosis between wild
boars and cattle: genotypical analysis of strains by molecular epidemiology techniques. J Clin
Microbiol, 37, 2766-2771.
224. Skuce R.A., McDowell S.W., Mallon T.R., Luke B., Breadon E.L., Lagan P.L., McCormick C.M.,
McBridge S.H. & Pollock J.M. 2005. Discrimination of isolates of Mycobacterium bovis in Northern
Ireland on the basis of variable numbers of tandem repeats (VNTRS). Vet Rec, 157, 501-501.
225. Snider W.R., Cohen E., Reif J.S., Stein S.C. & Prier J.E. 1971. Tuberculosis in canine and feline
populations. Am Rev Resp Dis, 104, 866-876.
226. Steele M.A., Burk R.F. & DesPrez R.M. 1991. Toxic hepatotoxicity with isoniazid and rifampin: a metaanalysis. Chest, 99, 465.
227. Stetter M.D., Mikota S.K., Gutter A.F., Monterroso E.R., Dalovisio J.R., Degraw C. & Farley T. 1995.
Epizootic of Mycobacterium bovis in a zoologic park. J Am Vet Med Assoc, 207 (12), 1618-1621.
228. Stumpff C.D. 1982. Epidemiologic study of an outbreak of bovine tuberculosis in confined elk herds.
In Proc. 86th Annual Meeting of the United States Animal Health Association, 7-12 November,
Nashville, Tennessee. Proc Ann Mtg USAHA, 86, 524-527.
229. Stumpff C.D., Essey M.A, Person D.H. & Thorpe D. 1984. Epidemiologic study of M. bovis in American
bison. In Proc. 88th Annual Meeting of the United States Animal Health Association, 21-26 October,
Fort Worth, Texas. Proc Ann Mtg USAHA, 88, 564-570.
230. Sunder S., Lanotte P., Godreuil S., Martin C., Boschiroli M.L. & Besnier J.M. 2009. Human-to-human
transmission of tuberculosis caused by Mycobacterium bovis in immunocompetent patients.
J Clinical Microbiol, 10, 1128.
231. Supply P., Allix C., Lesjean S., Cardoso-Oelemann M., Rusch-Gerdes S., Willery E., Savine E., de
Haas P., van Deutekom H., Roring S., Bifani P., Kurepina N., Kreiswirth B., Sola C., Rastogi N., Vatin V.,
Gutierrez M.C., Fauville M., Niemann S., Skuce R., Kremer K., Locht C. & van Soolingen D. 2006.
Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variablenumber tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol, 44 (12), 4498-4510.
232. Tarara R., Suleman M.A., Sapolsky R., Wabomba M.J. & Else J.G. 1985. Tuberculosis in wild olive
baboons, Papio Cynocephalus Anubis (Lesson), in Kenya. J Wildlife Dis, 21 (2), 137-140.

178

Vol. 45 (1), Vet Ital

www.izs.it/vet_italiana

© IZS A&M 2009

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

Tuberculosis: a re‐emerging disease in animals and humans

233. Tessaro S.V. 1986. The existing and potential importance of brucellosis and tuberculosis in Canadian
wildlife: a review. Can Vet J, 27 (3), 119-124.
234. Thoen C.O. 1993. Tuberculosis and other mycobacterial diseases of captive wild animals. In Zoo and
wild animal medicine, 3rd Edition (M.E. Fowler, ed.) W.B. Saunders, Philadelphia, Pennsylvania, 45-49.
235. Thoen C.O. 1994. Tuberculosis in wild and domestic mammals. In Tuberculosis: pathogenesis,
protection and control (B.R. Bloom, ed.). American Society for Microbiology Press, Washington, DC,
157-162.
236. Thoen C.O. 2006. Tuberculosis. In Diseases of swine, 9th Ed. (B.E. Straw, J.J. Zimmerman, S. D’Allaire &
D.J. Taylor, eds). Blackwell Publishing, Inc., Ames, Iowa, 807-816.
237. Thoen C.O. 2010. Tuberculosis In The Merck veterinary manual, 10th Ed. (C.M. Kahn & S. Line, eds).
Merck & Co., Inc., Whitehouse Station, New Jersey (in press).
238. Thoen C.O., Beluhan F.Z., Himes E.M., Capek V. & Bennett B.T. 1977. Mycobacterium bovis infection
in baboons (Papio papio). Arch Pathol Lab Med, 101, 291.
239. Thoen C.O., Richards W.D. & Jarnagin J.L. 1977. Mycobacteria isolated from exotic animals. J Am
Vet Med Assoc, 170, 987-990.
240. Thoen C.O., Mills K. & Hopkins M. 1980. Enzyme-linked immunosorbent assay reagent for detecting
antibodies in tuberculous exotic animals. Am J Vet Res 40 (5), 833-835.
241. Thoen C.O. & Karlson A.G. & Himes E.M. 1981. Mycobacterial infections in animals. Rev Infect Dis,
3 (5), 960-971.
242. Thoen C.O., Throlson K.J., Miller L.D., Himes E.M. & Morgan R.L. 1988. Pathogenesis of
Mycobacterium bovis infection in American bison. Am J Vet Res, 49 (11), 1861-1865.
243. Thoen C.O., Quinn W.J., Miller L.D., Stackhouse L.L., Newcomb B.F. & Ferell J.M. 1992.
Mycobacterium bovis infection in North American elk (Cervus elaphus). J Vet Diagn Invest, 4, 423427.
244. Thoen C.O. & Bloom B.R. 1995. Pathogenesis of Mycobacterium bovis. In Mycobacterium bovis
infection in animals and humans, 1st Ed. (C.O. Thoen & J.H. Steele, eds). Iowa State University Press,
Ames, Iowa, 3-14.
245. Thoen C.O., Schliesser T. & Kormendy B. 1995. Tuberculosis in captive wild animals.
In Mycobacterium bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele &
M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 93-104.
246. Thoen C.O. & LoBue P.A. 2007. Mycobacterium bovis tuberculosis: forgotten, but not gone. Lancet,
369, 1236-8.
247. Thoen C.O. & Barletta R.A. 2006. Pathogenesis of Mycobacterium bovis. In Mycobacterium bovis
infection in animals and humans, Chapter 4, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds).
Blackwell Publishing, Ames, Iowa, 18-33.
248. Thoen C.O. & Ebel E.D. 2006. Diagnostic tests for bovine tuberculosis. . In Mycobacterium bovis
infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell
Publishing, Ames, Iowa, 49-53.
249. Thoen C.O., LoBue P. & de Kantor I.N. 2006. The importance of Mycobacterium bovis as a zoonosis.
Vet Microbiol, 112, 339-345.
250. Thoen C.O., Williams D.E. & Thoen T.C. 2008. Discovery of streptomycin for treatment of tuberculosis.
One Health Newsletter, 1 (3), 5-6.
251. Thompson P.J., Cousins D.V., Gow B.L., Collins D.M., Williamson B.H. & Dagnia H.T. 1993. Seals, seal
trainers, and mycobacterial infection. Am Rev Respir Dis, 147, 164-167.
252. Thorel M.-F. 1980. Isolation of Mycobacterium africanum from a monkey. Tubercle, 61, 101-104.
253. Thorel M.-F., Karoui C., Varnerot A., Fleury C. & Vincent V. 1998. Isolation of Mycobacterium bovis
from baboons, leopards, and a sea lion. Vet Res, 29 (2), 207-212.
254. Tiruviluamala P. & Reichman L.B. 2002. Tuberculosis. Annu Rev Public Health, 23, 403-426.
255. Torres P.M. 2004. Situación de la tuberculosis bovina en la República Argentina. In Temas de
Zoonosis II (R. Cacchione, R. Durlach & O.P. Larghi, eds). Asociación Argentina de Zoonosis, Buenos
Aires, 235-242.
256. Towar D.R., Scott R.M. & Goyings L.S. 1965. Tuberculosis in a captive deer herd. Am J Vet Res,
26 (111), 339-346.
257. Tryland M. 2000. Zoonoses of arctic marine mammals. Infect Dis Res, 2 (2), 55-64.

© IZS A&M 2009

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

179

Tuberculosis: a re‐emerging disease in animals and humans

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

258. Twomey D.F., Cranshaw T.R., Anscombe J.E., Farrant L., Evans L.J., McElligott W.S., Higgins R.J.,
Dean G., Vordermeier M., Jahans K. & de la Rua-Domenech R. 2007. TB in llamas caused by
Mycobacterium bovis. Vet Res, 160 (5), 170.
259. United States Department of Agriculture (USDA), Animal and Plant Health Inspection Service (APHIS)
2004. Cattle from Mexico. APHIS, USDA, 9 CFR Part 93 (Docket No. 00-112-2). Fed Reg, 69 (41), 97499750 (edocket.access.gpo.gov/2004/04-4598.htm accessed on 12 February 2009).
260. van Soolingen D., Hermans P. W. & de Haas P.E. 1991. Occurrence and stability of insertion
sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequencedependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol, 29,
2578-2586.
261. Verma R. The status of Mycobacterium bovis in India In Mycobacterium bovis infection in animals
and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa,
161-172.
262. Vicente J., Hofle U., Garrido J.M., Fernandez-De-Mera I.G., Juste R., Barral M. & Gortazar C. 2006.
Wild boar and red deer display high prevalence of tuberculosis-like lesions in Spain. Vet Res, 37,107119.
263. Vincente J., Hofle U., Garrido J.M., Fernandez-De-Mera I.G., Acecedo P., Juste R., Barral M. &
Gortazar C. 2007. Risk factors associated with the prevalence of tuberculosis-like lesions in fenced
wild boar and red deer in south central Spain. Vet Res, 38, 451-464.
264. Vordermeier M., Goodchild A., Clifton-Hadley R. & de la Rua R. 2005. The interferon-gamma field
trial: background, principles and progress. Cattle Practice, 13 (4), 323-325.
265. Wahlstrom H., Carpenter T., Giesecke J., Anderson M., Englund L. & Vagsholm I. 2000. Herd-based
monitoring for tuberculosis in extensive Swedish deer herds by culling and meat inspection rather
than by intradermal tuberculin testing. Prev Vet Med. 43, 103-116.
266. Weiss R. 2006. Mycobacterium bovis infections in cattle in Germany. In Mycobacterium bovis
infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell
Publishing, Ames, Iowa, 246-247.
267. Wells A. & Oxon E. 1961. Tuberculosis in wild voles. Lancet, 1, 1221.
268. West G. 2006. Tuberculosis in captive exotic animals. In Mycobacterium bovis infection in animals
and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa,
248-257.
269. Weyer K., Fourie P.B., Durrheim D., Lancaster J., Haslov K. & Bryden H. 1999. Mycobacterium bovis as
a zoonosis in the Kruger National Park, South Africa. Int J Tuberc Lung Dis, 3 (12), 1113-1119.
270. Wilkins M.J., Meyerson J., Bartlett P.C., Spieldenner S.L., Berry D.E., Mosher L.B., Kaneene J.B.,
Robinson-Dunn B., Stobierski G. & Boulton M. 2006. Human Mycobacterium bovis infection and
bovine tuberculosis outbreak, Michigan, 1994-2007. Emerg Infect Dis, 14 (4), 1-4.
271. Wilson P., Weavers E., West B., Taylor M., Kavanagh J. & Jones P. 1984. Mycobacterium bovis
infection in primates in Dublin zoo: epidemiological aspects and implications for management. Lab
Anim, 18 (4), 383-387.
272. Wobeser G. 1995. Involvement of small wild animals in bovine tuberculosis. In Tuberculosis in wildlife
and domestic animals. Otago Conference Series No. 3. University of Otago Press, Dunedin, 267-269.
273. Wolf R.H., Gibson S.V., Watson E.A. & Baskin G.B. 1988. Multidrug chemotherapy of tuberculosis in
rhesus monkeys. Lab Anim Sci, 38, 25-33.
274. Wood P.R., Corner L.A., Rothel J.S., Baldock C., Jones S.L, Cousins D.B., McCormick B.S., Francis B.R.,
Creeper J. & Tweddle N.E. 1991. Field comparison of the interferon-gamma assay and the
intradermal tuberculin for the diagnosis of bovine tuberculosis. Aust Vet J, 68, 286-290.
275. Woodford M.H. 1982. Tuberculosis in wildlife in the Ruwenzori National Park Uganda (Part I). Trop
Anim Health Prod, 14 (2), 81-88.
276. Woods R., Cousins D.V., Kirkwood R. & Obendorf D.L. 1995. Tuberculosis in a wild Australian fur seal
(Arctocephalus pusillus doriferus) from Tasmania. J Wildlife Dis, 31 (1), 83-86.
277. World Health Organization (WHO) 1959. Joint WHO/FAO Expert Committee on Zoonoses, Second
Report. Geneva. Technical Report Series 169. WHO, Geneva.
278. World Health Organization (WHO) 2004. Anti-tuberculosis drug resistance in the world report no. 3
The WHO/IUATLD Global Project on anti-tuberculosis drug resistance surveillance. WHO, Geneva,
WHO/HTM/TB/2004.343, 152 pp.

180

Vol. 45 (1), Vet Ital

www.izs.it/vet_italiana

© IZS A&M 2009

Charles O. Thoen, Philip A. LoBue, Donald A. Enarson,
John B. Kaneene & Isabel N. de Kantor

Tuberculosis: a re‐emerging disease in animals and humans

279. World Health Organization (WHO) 2008. Estimated burden of TB, the Americas, 1990 and 2006. WHO,
Geneva, WHO Report 2008, Global Tuberculosis Control, 214 (www.who.int/tb/publications/
global_report/2008/pdf/annex3_amr.pdf accessed on 10 February 2009).
280. World Organisation for Animal Health (Office International des Épizooties: OIE). World animal health
information division, WAHID. disease information. Bovine tuberculosis 2008. (www.oie.int/wahis/
public.php?WAHIDPHPSESSID=ede022c8a9657a563a5200a845815222&page=disease&disease_type
=Terrestrial&disease_id=32&empty=999999 accessed on 10 February 2009).
281. Wyss D., Giacometti M., Nicolet J., Burnens A., Pfyffer G.E. & Audigi L. 2000. Farm and slaughter
survey of bovine tuberculosis in captive deer in Switzerland. Vet Rec, 147, 713-717.
282. Zendejas Martínez H., Milián Suazo F., Cuador Gil Q., Cruz Bello G., Anaya Escalera A.M., Huitron
Marquez G. & García Casanova L. 2007. Spatial epidemiology of bovine tuberculosis in Mexico. Vet
Ital, 43, 629-634.
283. Zhao D., Wu C. D. & Ning Z. Bovine tuberculosis in China. In Mycobacterium bovis infection in
animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele & M.J. Gilsdorf, eds). Blackwell Publishing,
Ames, Iowa, 244-245.
284. Zignol M., Hosseini M.S., Wright A., Weezenbeek C.L., Nunn P., Watt C.J., Williams B.G. & Dye C. 2006.
Global incidence of multidrug-resistant tuberculosis. J Infect Dis, 194, 479-485.
285. Zinsstag J., Kazawala R.R., Cadmus I. & Ayanwale L. 2006. Mycobacterium bovis in Africa.
In Mycobacterium bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele &
M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 199-210.
286. Zinsstag J., Schelling E., Roth F. & Kazawala R. 2006. Economics of bovine tuberculosis.
In Mycobacterium bovis infection in animals and humans, 2nd Ed. (C.O. Thoen, J.H. Steele &
M.J. Gilsdorf, eds). Blackwell Publishing, Ames, Iowa, 68-83.
287. Zumpe D., Silberman M.S. & Michael R.P. 1974. Unusual outbreak of tuberculosis due to
Mycobacterium bovis in a closed colony of rhesus monkeys (Macaca mulatta). Lab Anim Sci, 30,
237-240.

© IZS A&M 2009

www.izs.it/vet_italiana

Vol. 45 (1), Vet Ital

181

